Synergy CHC (SNYR) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 21, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Synergy CHC Corp.
Entity Central Index Key	1,562,733
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 14,100,000
Entity Common Stock, Shares Outstanding		88,764,357
Trading Symbol	SNYR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 2,517,642	$ 3,640,893
Restricted cash	100,000	607,084
Accounts receivable, net	2,195,391	3,979,857
Prepaid expenses	1,348,602	422,434
Inventory, net	1,102,777	686,655
Total Current Assets	7,264,412	9,336,923
Fixed assets, net	257,386	12,017
Goodwill	7,793,240	11,496,402
Intangible assets, net	5,145,434	5,915,262
Total Assets	20,460,472	26,760,604
Current Liabilities:
Accounts payable and accrued liabilities	4,558,919	5,032,102
Deferred revenue	36,000
Provision for income taxes payable	973,177	910,894
Earn out payment		2,551,500
Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party	5,890,903	3,025,669
Current portion of long-term notes payable	750,000	750,000
Warrant derivative liability		3,096,179
Total Current Liabilities	12,208,999	15,366,344
Long-term Liabilities:
Note payable		750,000
Royalty payable	313,752	258,897
Notes payable, net of debt discount and debt issuance cost, related parties	830,245	4,965,650
Total long-term liabilities	1,143,997	5,974,547
Total Liabilities	13,352,996	21,340,890
Commitments and contingencies
Stockholders' Equity:
Common stock, $0.00001 par value; 300,000,000 shares authorized; 88,764,357 and 81,692,954, shares issued and outstanding, respectively	888	817
Common stock to be issued (125,000 and 213,742 shares, respectively)	56,250	68,000
Additional paid in capital	16,400,316	13,920,735
Accumulated other comprehensive income	16,022
Accumulated deficit	(9,366,000)	(8,569,841)
Total stockholders' equity	7,107,476	5,419,713
Total Liabilities and Stockholders' Equity	$ 20,460,472	$ 26,760,604

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	88,764,357	81,692,954
Common stock, shares outstanding	88,764,357	81,692,954
Common stock to be issued shares	125,000	213,742

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 34,840,394	$ 13,456,377
Cost of Sales	10,205,324	5,308,130
Gross Profit	24,635,070	8,148,247
Operating expenses
Selling and marketing	10,334,075	3,685,727
General and administrative	8,019,722	3,368,495
Impairment of goodwill and intangible assets	2,176,910
Depreciation and amortization	1,170,778	608,002
Total operating expenses	21,701,485	7,662,224
Income from operations	2,933,585	486,023
Other (income) expenses
Interest income	(5,107)	(1,460)
Interest expense	1,567,867	958,740
Remeasurement loss (gain) on translation of foreign subsidiary	54,345	(7,740)
(Gain) loss on change in fair value of derivative liability	(1,380,600)	1,028,921
Amortization of debt discount	1,620,151	5,499,640
Amortization of debt issuance cost	215,302	154,525
Settlement expense	56,250
Loss on extinguishment of debt	657,180
Total other expenses	2,785,388	7,632,626
Net income (loss) before income taxes	148,197	(7,146,603)
Income tax expense	944,358	389,945
Net loss after tax	$ (796,161)	$ (7,536,548)
Net loss per share - basic and diluted	$ (0.01)	$ (0.11)
Weighted average common shares outstanding Basic and diluted	81,650,381	68,852,305
Comprehensive loss
Net loss	$ (796,161)	$ (7,536,548)
Foreign currency translation adjustment	16,022
Comprehensive loss	$ (780,139)	$ (7,536,548)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid In Capital [Member]	Common Stock To Be Issued [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2014	$ 621	$ 867,004	$ 40,000		$ (1,033,291)	$ (125,666)
Balance, shares at Dec. 31, 2014	62,100,000
Common stock issued for cash	$ 1	25,999				26,000
Common stock issued for cash, shares	40,000
Common stock issued as part of the Contribution Agreement with Hand MD	$ 21	1,499,978				1,500,000
Common stock issued as part of the Contribution Agreement with Hand MD, shares	2,142,857
Common stock issued for acquisitions of Breakthrough Products, Inc.	$ 30	2,549,970				2,550,000
Common stock issued for acquisitions of Breakthrough Products, Inc., shares	3,000,000
Common stock issued for acquisitions of NomadChoice Pty Ltd.	$ 36	1,749,964				1,750,000
Common stock issued for acquisitions of NomadChoice Pty Ltd., shares	3,571,428
Common stock issued to settle accounts payable	$ 3	204,997				205,000
Common stock issued to settle accounts payable, shares	292,857
Common stock issued for conversion of notes payable	$ 4	99,996				100,000
Common stock issued for conversion of notes payable, shares	400,000
Common stock issued for exercise of warrants	$ 101	(99)				2
Common stock issued for exercise of warrants, shares	10,145,812
Fair value of warrants issued along with notes payable		5,968,801				5,968,801
Fair value of vested stock options		523,714				523,714
Fair value of warrants issued to Breakthrough Products, Inc. as part of acquisition		430,411				430,411
Common stock to be issued for services			28,000			28,000
Common stock issued in conjunction with cancellation of warrants and options issued concurrent with debt
Foreign currency translation gain
Net loss					(7,536,548)	(7,536,548)
Balance at Dec. 31, 2015	$ 817	13,920,735	68,000		(8,569,839)	5,419,713
Balance, shares at Dec. 31, 2015	81,692,954
Common stock issued as part of the Contribution Agreement with Hand MD
Common stock issued for acquisitions of Breakthrough Products, Inc.
Common stock issued for acquisitions of NomadChoice Pty Ltd.
Common stock issued for conversion of notes payable
Fair value of warrants issued to Breakthrough Products, Inc. as part of acquisition
Common stock to be issued for services	$ 3	117,997	(68,000)			$ 50,000
Common stock to be issued for services, shares	285,170					71,428
Adjusting the value of goodwill for the value of shares issued related to acquisition of Breakthrough Products, Inc.		(1,170,000)				$ (1,170,000)
Common stock cancelled	$ (7)	(124,993)				(125,000)
Common stock cancelled, shares	(713,767)
Common stock to be issued			56,250			56,250
Common stock issued in conjunction with cancellation of warrants and options issued concurrent with debt	$ 75	1,456,417				1,456,492
Common stock issued in conjunction with cancellation of warrants and options issued concurrent with debt, shares	7,500,000
Fair value of vested stock options		2,200,160				2,200,160
Foreign currency translation gain				16,022		16,022
Net loss					(796,161)	(796,161)
Balance at Dec. 31, 2016	$ 888	$ 16,400,317	$ 56,250	$ 16,022	$ (9,366,000)	$ 7,107,476
Balance, shares at Dec. 31, 2016	88,764,357

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows from Operating Activities
Net loss	$ (796,161)	$ (7,536,548)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt issuance cost	215,302	154,525
Depreciation and amortization	1,170,778	608,002
Stock based compensation expense	2,200,160	551,714
Stock issued for services	50,000
Settlement expense	56,250
Loss on extinguishment of debt	657,180
Amortization of debt discount	1,620,151	5,499,640
Impairment of goodwill and intangible assets	2,176,910
Foreign currency transaction (gain) loss	(13,503)	54,600
Change in the fair value of derivative liability	(1,380,600)	1,028,921
Remeasurement loss (gain) on translation of foreign subsidiary	54,345	(7,740)
Non cash implied interest	114,213
Write-off of inventory	180,122
Bad debts		50,000
Changes in operating assets and liabilities:
Accounts receivable	1,734,466	(1,317,050)
Inventory	(547,295)	(19,632)
Prepaid expense and other current assets	(1,051,168)	(194,889)
Deferred revenue	36,000
Accounts payable and accrued liabilities	(438,530)	484,141
Net cash provided by (used in) operating activities	6,038,620	(644,316)
Cash Flows from Investing Activities
Payments for acquisition of fixed assets	(302,227)	(7,833)
Restricted cash	507,084	(607,084)
Payments for acquisition of Focus Factor		(4,500,000)
Payments for acquisition transaction with Knight Therapeutics Inc.		(250,000)
Payment of earn out liability	(2,551,500)
Payments for acquisition of NomadChoice Pty Ltd		(2,918,200)
Cash acquired in acquisitions		3,883,261
Net cash used in investing activities	(2,346,643)	(4,399,856)
Cash Flows from Financing Activities
Advances from related party notes		16,077
Proceeds from notes payable		11,500,000
Repayment of notes payable	(4,831,250)	(1,150,000)
Payment of debt issuance cost		(533,377)
Dividends paid		(1,173,975)
Proceeds from exercise of warrants		2
Proceeds from issuance of common stock		26,000
Net cash (used in) provided by financing activities	(4,831,250)	8,684,727
Effect of exchange rate on cash and cash equivalents	16,022
Net (decrease) increase in cash and cash equivalents	(1,123,251)	3,640,554
Cash and Cash Equivalents, beginning of period	3,640,893	338
Cash and Cash Equivalents, end of period	2,517,642	3,640,893
Supplemental Disclosure of Cash Flow Information:
Interest	1,488,123	806,740
Income taxes	864,864	12,688
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Common stock issued for conversion of notes payable		100,000
Beneficial conversion feature on warrants issued concurrent with debt		5,968,801
Derivative liability at inception		2,067,258
Assumption of liabilities as part of asset purchase agreement with Factor Nutrition Labs, LLC		1,912,827
Assumption of liabilities as part of acquisition transaction with Knight Therapeutics Inc.		969,532
Note issued as part of asset purchase agreement with Factor Nutrition Labs, LLC		1,500,000
Common stock issued as part of contribution agreement with Hand MD		1,500,000
Common stock issued for the acquisition of Breakthrough Products, Inc.		2,550,000
Common stock issued for the acquisition of NomadChoice Pty Ltd.		1,750,000
Fair value of warrants issued as part of acquisition of Breakthrough Products, Inc.		430,411
Net liabilities taken over as part of acquisition of Breakthrough Products, Inc.		422,749
Net assets taken over as part of acquisition of NomadChoice Pty Ltd.		70,801
Common stock issued to settle payables		205,000
Reallocation of goodwill related to acquisition of Factor Nutrition to intellectual property	450,000
Reallocation of goodwill related to acquisition of Breakthrough Products, Inc. to intellectual property	150,000
Reallocation of non-compete agreement related to acquisition of Breakthrough Products, Inc. to goodwill	50,000
Adjusting the value of goodwill for the value of shares issued related to acquisition of Breakthrough Products, Inc.	1,170,000
Reallocation of blogger database and intellectual property related to acquisition of Nomadchoice Pty Ltd. to customer database	215,000
Common stock to be issued now issued	68,000
Cancellation of common stock	125,000
Common stock issued in conjunction with cancellation of warrants and options issued concurrent with debt	1,456,492
Adjustment of accounts receivable and payables created during acquisition of Neuragen	24,592
Inventory written-off and adjusted against accounts receivable and payables created during acquisition of Neuragen	$ 48,949

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Note 1 – Nature of the Business Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.” The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisition. Synergy is the sole owner of five subsidiaries: Neuragen Corp., Breakthrough Products, Inc., NomadChoice Pty Ltd., Synergy CHC Inc., and Sneaky Vaunt Corp., and the results have been consolidated in these statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2016 and 2015 significant estimates included are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, impairment analysis of goodwill and intangible assets, estimates used in the fair value calculation of stock based compensation, beneficial conversion feature and derivative liability on warrants using Black-Scholes Model. Cash and Cash Equivalents The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2016 and 2015 the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2016 and 2015, the uninsured balances amounted to$2,038,985 and $3,453,290, respectively. Capitalization of Fixed Assets The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. Accounts receivable Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of December 31, 2016 and 2015, allowance for doubtful accounts was $0 and $121,291, respectively. Advertising Expense The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling and marketing expense in the accompanying consolidated statements of operations. Research and Development Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred. Income Taxes The Company utilizes FASBASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made. Net Earnings (Loss) Per Common Share The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of December 31, 2016 and 2015, options to purchase 6,300,000 and 5,000,000 shares of common stock, respectively, were outstanding. As of December 31, 2016 and 2015, warrants to purchase 1,000,000 and 9,132,002 shares of common stock, respectively, were outstanding. These potential shares were excluded from the shares used to calculate diluted loss per share as their inclusion would reduce net loss per share. Going Concern The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at December 31, 2016 of $9,366,000. The Company had a working capital deficit of $4,944,587 as of December 31, 2016. During the year ended December 31, 2016, the Company incurred net loss of $796,161. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs and has income from operations of $2,933,585. The ability of the Company to continue as a going concern is dependent on the Company continuing to execute the sales of their products. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Fair Value Measurements The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure. ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 - Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2016, the Company has determined that there were no assets or liabilities measured at fair value. Inventory Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. Intangible Assets with Indefinite Lives We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization except intellectual property of $1,450,000 acquired as part of Asset Purchase Agreement entered into with Factor Nutrition LLC on January 22, 2015. As of December 31, 2016 and 2015, our qualitative analysis of intangible assets with indefinite lives did not indicate any impairment. Long-lived Assets Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of December 31, 2015, our qualitative analysis of long-lived assets did not indicate any impairment. However, as of December 31, 2016 our review of intangible assets related to one of our subsidiaries did indicate that the carrying amount of the asset may not be recoverable. During the year ended December 31, 2016, the Company fully impaired related intangible assets and charged to operations impairment loss of $193,750. Goodwill An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of December 31, 2015 our qualitative analysis of goodwill did not indicate any impairment. However, as of December 31, 2016, our review of Goodwill related to one of our subsidiaries did indicate that the carrying amount of the asset may not be recoverable. During the year ended December 31, 2016, the Company fully impaired related goodwill and charged to operations impairment loss of $1,983,160. Foreign Currency Translation The functional currency of one of the Company’s foreign subsidiaries (Nomadchoice Pty Ltd.) is the U.S. Dollar. The Company’s subsidiary maintains its record using local currency (Australian Dollar). All monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at fiscal year-end exchange rates, non-monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as remeasurement gain or loss on translation of foreign subsidiary. The functional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income. Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred. Concentrations of Credit Risk In the normal course of business, the Company provides credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns. Warehousing costs Warehouse costs include all third party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales. Product display costs All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred. Warrant Derivative Liabilities ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. A Black-Scholes-Merton option-pricing model, with dilution effects, was utilized to estimate the fair value of the Warrant Derivative Liabilities as of November 12, 2015 and December 31, 2015. As of December 23, 2016 the Warrant Derivative Liability was extinguished in conjunction with the issuance of shares. This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 December 23, 2016 Stock Price $ 0.46 $ 0.69 $ 0.39 Exercise Price $ 0.49 $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 8.92 Stock Volatility 157.56 % 152.07 143.15 % Risk-Free Rate 2.32 % 2.27 2.55 % Dividend Rate 0 % 0 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243 4,547,243 Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs. Debt Issuance Costs Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt facilities. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses. Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties shall be recorded at fair value of the goods or services exchanged. Segment Reporting Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. Reclassification of Prior Period Presentation Certain reclassifications have been made to conform the prior period data to the current presentations. These reclassifications had no effect on the reported results. Recent Accounting Pronouncements ASU 2016-18 In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), which requires that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently evaluating the impact of adopting ASU 2016-18 on our consolidated financial statements. ASU 2016-15 In August 2016, the FASB issued AS 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The effective date for ASU 2016-15 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently evaluating the impact of adopting ASU 2016-18 on our consolidated financial statements. ASU 2016-10 In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-10 on its consolidated financial statements. ASU 2016-09 In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation, or ASU No. 2016-09. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements. ASU 2016-08 In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its consolidated financial statements. ASU 2016-01 In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. ASU 2015-17 In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. Currently deferred taxes for each tax jurisdiction are presented as a net current asset or liability and net noncurrent asset or liability on the balance sheet. To simplify the presentation, the new guidance requires that deferred tax liabilities and assets for all jurisdictions along with any related valuation allowances be classified as noncurrent in a classified statement of financial position. This guidance is effective for interim and annual reporting periods beginning after December 15, 2016, and early adoption is permitted. The Company adopted this guidance in the fourth quarter of the year ended December 31, 2015 on a retrospective basis. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements., and did not have any effect on prior periods due to the full valuation allowance against the Company’s net deferred tax assets. ASU 2015-16 In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement –Period Adjustments. Changes to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and, instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for both public and private companies for periods beginning after December 15, 2015. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2015-14 In August 2015, the FASB issued ASU No. 2015-14, Revenue From Contracts With Customers (Topic 606). The amendments in this ASU defer the effective date of ASU 2014-09. Public business entities should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are still evaluating the effect of the adoption of ASU 2014-09 on our consolidated financial statements. ASU 2015-11 In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out (“LIFO”) method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. We do not expect the adoption of ASU 2015-11 to have a material effect on our consolidated financial statements. ASU 2015-05 In April 2015, the FASB issued ASU 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40). ASU 2015-05 provides guidance regarding the accounting for a customer’s fees paid in a cloud computing arrangement; specifically about whether a cloud computing arrangement includes a software license, and if so, how to account for the software license. ASU 2015-05 is effective for public companies’ annual periods, including interim periods within those fiscal years, beginning after December 15, 2015 on either a prospective or retrospective basis. Early adoption is permitted. Adoption of this new standard did not have any impact on the

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisitions	Note 3 – Acquisitions Asset Purchase Agreement with Factor Nutrition Labs, LLC: On January 22, 2015 (the “Closing Date”), the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Factor Nutrition Labs, LLC, a Delaware limited liability company (the “Seller”), Vita Partners, LLC, RPR Partners, LLC, and Thor Associates, Inc. (each a “Principal Owner”). Pursuant to the Purchase Agreement, the Company purchased all of the assets of the Seller’s line of business and products called FOCUS Factor (the product plus the business related to the product is collectively referred to as the “Focus Factor Business”) and assumed the accounts payable and contractual obligations of the Focus Factor Business for an aggregate purchase price of $6.0 million, with $4.5 million paid on the Closing Date, and $750,000 to be paid on or before January 20, 2016 and an additional $750,000 to be paid on or before January 20, 2017. Distribution Agreement On January 22, 2015, the Company and Knight entered into a Distribution, License and Supply Agreement (the “Distribution Agreement”), pursuant to which the Company granted to Knight an exclusive license to commercialize FOCUSFactor, FOCUSFactor Kids and Synergy Strip and all improvements thereto (together the “Licensed Products”) and appointed Knight as the exclusive distributor to offer to sell and sell the Licensed Products in Canada, and, at Knight’s election, one or more of Israel, Russia, and Sub-Saharan Africa. The Distribution Agreement provides that Knight may sublicense its rights or use sub-distributors under the Distribution Agreement on terms consistent with the terms of the Distribution Agreement. During the term of the Distribution Agreement, Knight agrees to obtain from the Company all its requirements for the Licensed Products and the Company agrees to supply the Licensed Products at its adjusted production cost plus a designated percentage and any applicable taxes. In the event of a long term inability by the Company to supply Knight with the Licensed Products, Knight is entitled to require, among other remedies, the Company to grant a Knight-designated third party a non-exclusive license to use all relevant intellectual property to manufacture and supply Knight with the Licensed Products for commercialization in the Territory. The term of the Distribution Agreement runs until 15 years from the date of the first commercial sale of a Licensed Product in Canada, and the Distribution Agreement will automatically renew for successive 15-year periods unless either party provides the other with written notice of its intention not to renew (a “Non-Renewal Notice”). The Company agrees that in the event it issues a Non-Renewal Notice, the Company will pay to Knight a non-renewal fee equal to the net sales of the Licensed Products achieved by Knight in the Territory during the eight calendar quarters preceding the date of such notice, plus all applicable taxes. Distribution Option Agreement In connection with the Loan Agreement, the Company entered into a Product Distribution Option Agreement, dated January 22, 2015 (the “Option Agreement”), pursuant to which the Company granted Knight the exclusive right to negotiate the exclusive distribution rights of any one or more of the Company’s products, including products from the Focus Factor Business, for the territories of Canada, Russia, Sub-Saharan Africa and Israel (the “Option”), pursuant to designated parameters. The Option Agreement is effective upon the date of the Option Agreement, will run until January 31, 2045, and will automatically renew thereafter for successive five-year periods unless either party provides a notice of termination prior to the Option Agreement’s expiration. If Knight does not exercise the option then the Company is free to contract for distribution with other parties, but only on terms no less favorable than those offered by Knight pursuant to the Option Agreement. On December 3, 2015, we entered into an Amendment to First Amendment Agreement (the “Second Amendment Agreement”) with Knight pursuant to which we agreed to grant distribution rights to Knight for Breakthrough’s products. To satisfy this obligation, on December 3, 2015, we also entered into an Amendment and Confirmation Agreement (the “Confirmation Agreement”) with Knight, Nomad and Breakthrough to amend the Distribution, License and Supply Agreement dated January 22, 2015 (the “Distribution Agreement”) between us and Knight to grant to Knight an exclusive license to commercialize any and all Nomad and Breakthrough products and appoint Knight as the exclusive distributor to offer and sell those products in Canada, Israel, Romania, Russia and each of the countries within Sub-Saharan Africa, which is the new “Territory” under the Distribution Agreement, as amended. Pursuant to the Second Amendment Agreement, Nomad will buy all Flat Tummy Tea products within the Territory for direct to consumer sales exclusively from Knight and/or its affiliates at cost of goods plus 60% of gross sales. The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on January 22, 2015. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts receivable $ 2,733,167 Inventory 67,113 Intellectual property 1,000,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 2,071,517 Liabilities Accounts payable (971,381 ) Accrued expenses (941,446 ) $ 6,000,000 During first quarter 2016 filing, the Company has consulted with a valuation professional to assist in determining the fair value of the identifiable FOCUSfactor intangible assets. As a result of this work, the Company has increased the amount allocated to the FOCUSfactor indefinite-lived brand and patent by $450,000 and reduced the amount recorded to goodwill by an identical amount. This adjustment had no effect on the income statement. The Company believes that the restated amount of $1,450,000 properly states the fair value of the FOCUSfactor brand and patent. The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Accounts receivable $ 2,733,167 Inventory 67,113 Intellectual property 1,450,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 1,621,517 Liabilities Accounts payable (971,381 ) Accrued expenses (941,446 ) $ 6,000,000 The Customer relationships, the non-compete and the non-solicitation provisions will be amortized over their estimated useful lives of 5 years. Intellectual property is not amortized and will be tested for impairment. During the years ended December 31, 2016 and 2015, the Company charged to operations amortization expense of $408,206 and $384,720, respectively. The purchase price allocated to the acquisition of the assets of Factor Nutrition Labs, LLC is made up as follows: Amount Cash payment made on January 22, 2015 $ 4,500,000 Cash payment made on January 20, 2016 750,000 Cash payment to be made on January 20, 2017 750,000 Total $ 6,000,000 Asset Purchase Agreement with Knight Therapeutics Inc.: On June 26, 2015 (the “Closing Date”), Neuragen Corp., a Delaware corporation (“Neuragen”) and our wholly owned subsidiary, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Knight Therapeutics Inc., a Canadian corporation (“Knight Canada”). Pursuant to the Purchase Agreement, Neuragen purchased the U.S. rights related to an innovative OTC product that helps relieve pain caused by diabetic nerve damage (the “Purchased Assets”) for an aggregate purchase price of $1.2 million, with (i) $250,000 paid on the Closing Date, (ii) $250,000 to be paid on or before June 30, 2016, (iii) $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and (iv) 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million (collectively, “Total Consideration”). The Company has recorded present value of future payments of $290,947 and $531,589 as of December 31, 2016 and 2015, respectively. The Company has recorded interest expense of $59,358 and $37,372 for the years ended December 31, 2016 and 2015, respectively. Security Agreement On the Closing Date, Neuragen entered into a Security Agreement with Knight Canada, pursuant to which Neuragen granted a lien and security interest to Knight Canada in Collateral in connection with the Purchase Agreement. The Security Agreement was made to secure the payment of all indebtedness, obligations and liabilities of Neuragen of the Purchase Agreement, including all expenses and charges, legal or otherwise, suffered or incurred by Knight Canada in collecting or enforcing such indebtedness of the Purchase Agreement. The Security Agreement includes customary events of default, including but not limited to: payment defaults; Neuragen becoming insolvent or entering into bankruptcy; or if any contemplated security ceases to be a valid and perfected first-priority security interest that is not remedied within fifteen business days by Neuragen. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of the outstanding Total Consideration will bear a default interest rate of an additional 10% per annum. The acquisition was treated as an acquisition of assets as the transaction involved the acquisition of a brand and a license agreement. The allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts receivable $ 58,054 Inventory 204,925 Intangible property 100,000 License agreement 606,553 Liabilities Accounts payable (51,795 ) Accrued expenses (148,520 ) $ 769,217 The intangible property and license agreement will be amortized over their estimated useful lives of 5 years. During the year ended December 31, 2016 and 2015, the Company charged to operations amortization expense of $141,311 and $70,655, respectively. Contribution Agreement with Hand MD Corp.: On August 18, 2015 (the “Closing Date”), we entered into a Contribution Agreement with Hand MD Corp., a Delaware corporation, whereby we contributed to Hand MD Corp. 2,142,857 shares of our common stock in exchange for 50% of Hand MD Corp.’s outstanding capital securities valued at $0.70 per share. Simultaneously, Hand MD, LLC, a California limited liability company, entered into a Contribution Agreement with Hand MD Corp., the principal owners of Hand MD, LLC, and us whereby Hand MD LLC contributed to Hand MD Corp. all of its right, title and interest in its intellectual property associated with skincare, nail care and nail polish products (the “Hand MD Business”) in exchange for the other 50% of Hand MD Corp.’s outstanding capital securities. In the Contribution Agreement among Hand MD Corp., Hand MD, LLC, the principal owners of Hand MD, LLC and us, Hand MD, LLC and its principal owners agreed to not compete or solicit customers or employees for five years. As part of the transaction, we also purchased from Hand MD Corp. all inventory related to the Hand MD Business for approximately $106,000. The Company has recorded 50% of the present value of future royalty payments of $313,752 and $258,897 as of December 31, 2016 and 2015, respectively. We also entered into a license agreement with Hand MD Corp. on August 18, 2015, whereby we acquired the exclusive worldwide license to commercialize Hand MD Corp. skincare products and all improvements thereto. The license runs in perpetuity unless earlier terminated. We will pay Hand MD Corp. a royalty of 5% of the net sales price of product sold, transferred or otherwise disposed of by us, as well as 5% of any amount we receive from sublicensees, subject to a minimum royalty of $250,000 in the second year of the license and $500,000 in the third year of the license, after which the minimum royalty terminates. We are solely responsible for any regulatory and intellectual property filings, including those necessary to maintain regulatory approvals for the licensed products. Either we or Hand MD Corp. can terminate the agreement in the event of bankruptcy or insolvency of the other party, or the uncured material breach of the agreement by the other party. Upon termination we would be entitled to sell any inventory of licensed product in the normal course of business and consistent with sales of licensed product during the term of the agreement. The Contribution Agreements and the License Agreement contain customary representations and warranties and covenants by the respective parties. We also entered into a Consulting Agreement on August 18, 2015, with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related services. We will pay Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. If we terminate the Consulting Agreement without cause, we will be obligated to pay the remaining term of the Agreement. Ms. Harshbarger agreed not to compete with us in the United States in any marketing or sales of skincare, nail polish and nail care products during the term of the Consulting Agreement and for 12 months after its termination. Ms. Harshbarger also agreed not to solicit customers or employees for the same period. The acquisition was treated as an acquisition of assets as the transaction involved the acquisition of a brand and a license agreement. The allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Intangible property $ 100,000 License agreement 1,670,675 Liabilities - Royalty payable (258,897 ) Others (11,778 ) $ 1,500,000 The intangible property and license agreement will be amortized over their estimated useful lives of 5 years. During the years ended December 31, 2016 and 2015, the Company charged to operations amortization expense of $354,135 and $118,045, respectively. Stock Purchase Agreement with Breakthrough Products, Inc.: On November 12, 2015 (the “UrgentRx Closing Date”), we entered into a Stock Purchase Agreement (the “UrgentRx SPA”) with Breakthrough Products, Inc., a Delaware corporation (the “Company”), URX ACQUISITION TRUST, a Delaware statutory trust, (the “Trust”), Jordan Eisenberg, the chief executive officer and a shareholder of the Company (“Eisenberg”), and the other shareholders of the Company (Eisenberg and such other shareholders collectively referred to as the “UrgentRx Sellers”) for the purchase of all the issued and outstanding capital stock of the Company for 6,000,000 shares of our common stock (“UrgentRx Equity Consideration”). In addition to the UrgentRx Equity Consideration, we have agreed to pay a royalty to the Trust, for the benefit of the UrgentRx Sellers, equal to 5% of gross sales of the UrgentRx (as defined below) following the first $5,000,000 in gross sales by the UrgentRx Products, on a quarterly basis for a period of seven years from the UrgentRx Closing Date. The Company is engaged in the business of developing and selling medications for headache, heart burn, allergy attack, ache and pain, and upset stomach in the form of powders (“UrgentRx”). Following the UrgentRx Closing Date, we discovered certain liabilities and obligations of Breakthrough that required an adjustment to the UrgentRx Equity Consideration and the royalty payments. On December 17, 2015, we entered into a Settlement and Release Agreement (the “Settlement Agreement”) with the UrgentRx Sellers, the Trust, on its own behalf and as the representative of the UrgentRx Sellers, David T. Leyrer, Michael Valentino, Ron Fugate, and Randall Kaplan (collectively with Leyrer, Valentino, Fugate, the “Former Directors”) to resolve the post-closing liabilities. Pursuant to the terms of the Settlement Agreement, 3,000,000 shares of the Equity Consideration were returned by the Trust to us and our obligation to pay royalties to the Trust was reduced from seven years to five years. The Settlement Agreement further contained mutual releases among us, the UrgentRx Sellers, and the Former Directors, with limited exceptions. Additionally, we issued a three-year warrant to the Trust with a $5.00 per share exercise price. We may redeem the warrant at a price of $0.001 per share if our common stock is traded on the OTCBB or on a national securities exchange, and the per share closing sale price of our common stock equals or exceeds the exercise price for a period of 90 consecutive calendar days. In the event of a reorganization or reclassification of our capital stock, the merger or consolidation of our company into another entity or the sale or transfer of all or substantially all of our assets, the warrant will terminate if not exercised prior to the date of such event. The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on November 12, 2015. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 2,298,619 Accounts receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 3,253,160 Liabilities Accounts payable (741,822 ) Accrued expenses (2,202,848 ) $ 2,980,411 The preliminary purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 2,550,000 Stock warrants issued 430,411 Total $ 2,980,411 During second quarter 2016 filing, the Company has consulted with a valuation professional to assist in determining the fair value of the identifiable Breakthrough Products, Inc.’s intangible assets. As a result of this work, the Company has increased the amount allocated to the UrgentRx patent by $150,000, decreased the amount allocated to a Non-Compete agreement by $50,000 and reduced the amount recorded to goodwill by the identical amounts. In addition, it was determined that an incorrect stock price was used to calculate the purchase price of the transaction. As a result of this determination, the Company decreased Additional Paid In Capital and Goodwill by $1,170,000. These adjustments had no effect on the income statement. The Company believes that these restated amounts properly state the fair value of the Breakthrough Products, Inc. transaction. The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Cash $ 2,298,619 Accounts receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 250,000 Non-compete provision - Goodwill 1,983,160 Liabilities Accounts Payable (741,822 ) Accrued Expenses (2,202,848 ) $ 1,810,411 The Intellectual property will be amortized over its estimated useful live of 5 years and the non-compete provision will be amortized over its term of 3 years. During the years ended December 31, 2016 and 2015, the Company charged to operations amortization expense of $51,667 and $4,583, respectively. As of December 31, 2016 our review of intangible assets and Goodwill related to UrgentRx did indicate that the carrying amount of these assets may not be recoverable. It was determined that the net balance of $193,750 of intangible assets and $1,983,160 of Goodwill would be fully impaired and accordingly the Company recorded impairment loss of $2,176,910 during the year ended December 31, 2016. The adjusted purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 1,380,000 Stock warrants issued 430,411 Total $ 1,810,411 Stock Purchase Agreement with TPR Investments Pty Ltd: On November 15, 2015 (the “Flat Tummy Tea Closing Date”), we entered into a Stock Purchase Agreement (the “Flat Tummy Tea SPA”) with TPR Investments Pty Ltd ACN 128 396 654 as trustee for Polmear Family Trust (the “Flat Tummy Tea Seller”), Timothy Polmear and Rebecca Polmear and NomadChoice Pty Limited ACN 160 729 939 trading as Flat Tummy Tea, an Australian proprietary limited company (“NomadChoice”) for the purchase of all the issued and outstanding capital stock of NomadChoice for $4,000,000 (AUD) in cash consideration (the “Cash Consideration”) and 3,571,428 shares of our common stock (“Flat Tummy Tea Equity Consideration”). In addition to the Cash Consideration and the Flat Tummy Tea Equity Consideration, we have also agreed to pay the Flat Tummy Tea Seller certain earn-out payments of up to $3,500,000 (AUD) in aggregate upon certain EBITDA thresholds are met as of June 30, 2016, as described in the Flat Tummy Tea SPA. This earn-out payment was distributed on March 4, 2016. Flat Tummy Tea is engaged in the business of developing, manufacturing, and selling herbal detox tea (“Flat Tummy Tea”). The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on November 1, 2015. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 1,584,642 Other receivable 30,684 Inventory 134,212 Prepaid expenses 141,070 Fixed assets, net 5,698 Intangible assets, Net 3,493 Blogger database 200,000 Customer database 500,000 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 6,174,899 Liabilities Accounts payable (77,064 ) Accrued expenses (56,224 ) Dividends payable (1,177,152 ) Provision for income tax (518,558 ) $ 7,095,700 During second quarter 2016 filing, the Company has consulted with a valuation professional to assist in determining the fair value of the identifiable NomadChoice’s intangible assets. As a result of this work, the Company has increased the amount allocated to the Customer Database by $215,000, decreased the amount allocated to Intellectual Property by $100,000 and decreased the amount allocated to the Blogger Database by $115,000. These adjustments had no effect on the income statement. The Company believes that these restated amounts properly state the fair value of the TPR Investments Pty Ltd. transaction. The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Cash $ 1,584,642 Other receivable 30,684 Inventory 134,212 Prepaid expenses 141,070 Fixed assets, net 5,698 Intangible assets, Net 3,493 Blogger database 85,000 Customer database 715,000 Intellectual property - Non-compete provision 50,000 Goodwill 6,174,899 Liabilities Accounts payable (77,064 ) Accrued expenses (56,224 ) Dividends payable (1,177,152 ) Provision for income tax (518,558 ) $ 7,095,700 The Blogger Database, Customer Database, Intellectual property and non-compete provision will be amortized over its estimated useful lives of 5 years. During the years ended December 31, 2016 and 2015, the Company charged to operations amortization expense of $170,000 and $28,333, respectively. The purchase price allocated to the acquisition of the assets of NomadChoice is made up as follows: Cash $ 2,848,800 Stock issued at closing 1,750,000 Earn-out payment 2,496,900 Total $ 7,095,700

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 4 – Income Taxes The Company utilizes FASBASC740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forwards. Based upon Management’s evaluation, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the benefit derived from net operating loss carry-forwards. Deferred income taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not have any uncertain tax positions. Income tax expense for the years ended December 31, 2016 and 2015 was $944,358 and $389,945, respectively, due to Foreign Income Tax relating to NomadChoice in Australia. The table below summarizes the differences between the U.S. statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2016 and 2015: December 31, 2016 December 31, 2015 U.S. Statutory Rate 34 % 34 % U.S. effective rate in excess of AU/CA rate (1 )% (1 )% U.S. valuation allowance (34 )% (34 )% Foreign Tax - Australia 638 % 6.8 % Total provision for income taxes 637 % 5.8 % The Company has deferred tax assets, which have been fully reserved, as follows as of December 31, 2016 and 2015: December 31, 2016 December 31, 2015 Deferred tax assets $ 12,950,124 $ 11,460,536 Valuation allowance for deferred tax assets (12,950,124 ) (11,460,536 ) Net deferred tax assets $ - $ - Taxes accrued and paid for the tax year December 31, 2016 are attributable to NomadChoice Pty, Ltd., the Company’s wholly-owned subsidiary and is subject to income taxes in the jurisdiction in which it operates, Australia. Tax expense was $944,358 and $389,945 for 2016 and 2015, respectively. The effective tax rate is attributable to the Company’s world wide income/(loss) as it relates to the income tax expense due in Australia. Earnings in foreign subsidiaries are permanently reinvested and the Company does not have plans to pay a dividend from such subsidiaries for the foreseeable future. The Company also has net operating loss carryforwards of approximately $32,720,733 and $25,137,583 included in the deferred tax asset table above for 2016 and 2015, respectively, the majority attributable to the acquisition of Breakthrough Products, Inc. However, due to limitations of carryover attributes and separate return limitation year rules, it is unlikely the company will benefit from the NOL’s and thus Management has determined a 100% valuation reserved is required. Further, the Company has not completed an evaluation of the NOL’s attributable to Breakthrough Products, Inc. at the date of this report. The total deferred tax asset is calculated by multiplying a domestic (US) 34 percent marginal tax rate for 2016 and 34 percent marginal tax rate for 2015 by the cumulative Net Operating Loss Carryforwards (“NOL”).The Company currently has net operating loss carryforwards approximately aggregating $32,720,733 and $33,707,458 for 2016 and 2015, respectively, which expire through 2035. The deferred tax asset related to the NOL carryforwards Management has determined based on all the available information that a 100% Valuation reserve is required. For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382, change of ownership rules. If the Company has had a change in ownership, the NOL’s would be limited as to the amount that could be utilized each year, based on the Code.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following: December 31, 2016 December 31, 2015 Trade accounts receivable $ 2,195,391 $ 4,101,148 Less allowances - (121,291 ) Total accounts receivable, net $ 2,195,391 $ 3,979,857 During the year ended December 31, 2016 and 2015, the Company charged $0 and $50,000, respectively to bad debt expense in setting up an allowance.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	Note 6 – Prepaid Expenses At December 31, 2016 and 2015, prepaid expenses consisted of the following: December 31, 2016 December 31, 2015 Advances for inventory $ 188,980 $ 171,494 Media production 207,555 55,849 Insurance 70,392 54,519 Trade shows 46,700 45,700 Deposits 6,228 41,228 Consultants 15,000 24,000 Rent 15,452 16,216 Promotion - Bloggers 426,220 - License agreement 258,333 - Software subscriptions 88,782 - Miscellaneous 24,960 13,428 Total $ 1,348,602 $ 422,434

Concentration of Credit Risk

Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	Note 7 – Concentration of Credit Risk Cash and cash equivalents The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2016 and 2015, the uninsured balance amounted to $2,038,985 and $3,453,290, respectively. Accounts receivable As of December 31, 2016 and 2015, three customers accounted for 91% and 93%, respectively of the Company’s accounts receivable. Major customers For the year ended December 31, 2016, three customers accounted for approximately 34% of the Company’s net revenue. For the year ended December 31, 2015, three customers accounted for approximately 73% of the Company’s net revenue. Substantially all of the Company’s business is with companies in the United States. Major suppliers For the year ended December 31, 2016 and 2015, our products were made by the following suppliers: FOCUSfactor Atrium Innovations - Pittsburgh, PA Vit-Best Nutrition, Inc. - Tustin, CA Flat Tummy Tea Caraway Tea Company, LLC - Highland, NY - Neuragen C-Care, LLC - Linthicum Heights, MD - UrgentRx Capstone Nutrition - Ogden, UT - Hand MD HealthSpecialty - Santa Fe Springs, CA It is the opinion of management that the products can be produced by other manufacturers and the choice to utilize these suppliers is not a significant concentration.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Note 8 – Inventory Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. The carrying value of inventory consisted of the following: December 31, 2016 December 31, 2015 Finished goods $ 474,420 $ 535,908 Components 431,241 115,340 Inventory in transit 104,500 - Raw Materials 92,616 35,406 Total inventory $ 1,102,777 $ 686,654 As of January 22, 2015, inventory was pledged to Knight under the Loan Agreement (see note 12). As of December 31, 2016, $104,500 of the Company’s inventory was in transit.

Fixed Assets and Intangible Ass

Fixed Assets and Intangible Assets	12 Months Ended
	Dec. 31, 2016
Assets
Fixed Assets and Intangible Assets	Note 9 – Fixed Assets and Intangible Assets As of December 31, 2016 and 2015, fixed assets and intangible assets consisted of the following: December 31, 2016 December 31, 2015 Property and equipment $ 308,084 $ 18,187 Less accumulated depreciation (50,698 ) (6,170 ) Fixed assets, net $ 257,386 $ 12,017 Depreciation expense for the years ended December 31, 2016 and 2015 was $44,480 and $1,513, respectively. December 31, 2016 December 31, 2015 FOCUSfactor intellectual property $ 1,450,000 $ 1,000,000 Intangible assets subject to amortization 5,373,017 5,521,751 Less accumulated amortization and impairment (1677,583 ) (606,489 ) Intangible assets, net $ 5,145,434 $ 5,915,262 Amortization expense for the years ended December 31, 2016 and 2015 was $1,126,298 and $606,489, respectively. Impairment of intangible assets for the years ended December 31, 2016 and 2015 was $193,750 and $0, respectively. These intangible assets were acquired through Asset Purchase Agreement and Stock Purchase Agreements disclosed in Note 3. The estimated aggregate amortization expense over each of the next five years is as follows: 2017 $ 1,074,650 2018 1,074,576 2019 1,074,311 2020 471,897 2021 -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions On April 2, 2014, the Company granted 1,000,000 options valued at approximately $282,000 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company (see note 15). On October 31, 2014, the Company borrowed $100,000 through a promissory note bearing interest at 10% with a maturity date of October 31, 2015 from a company owned by Mr. Ross, the Company’s Chief Executive Officer. During the year ended December 31, 2015, the note was converted into 400,000 shares of the Company’s common stock. The Company accrued and paid consulting fees of $25,000 and $15,000 per month in 2016 and 2015, respectively, to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $481,215 and $180,000, respectively during 2016 and 2015 as consulting fees and bonuses, and made payments totaling $481,215 and $486,958 towards services to an entity owned and controlled by an officer and shareholder of the Company for the year ended December 31, 2016 and 2015. As of December 31, 2016 and 2015, the total outstanding balance was $0. On January 22, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for the purchase of the Focus Factor assets. At December 31, 2016 and 2015, the Company owed Knight $2,752,639 and $4,267,268, respectively, on this loan, net of discount (see Note 12). On June 26, 2015, the Company entered into a Security Agreement with Knight Therapeutics, Inc., through its wholly owned subsidiary Neuragen Corp., for the purchase of Knight Therapeutics, Inc.’s assets. At December 31, 2016 and 2015, the Company owed Knight $625,000 and $925,000 in relation to this agreement (see Note 12). On August 18, 2015, the Company entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related service. The Company will pay Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. Hand MD, LLC is a 50% owner in Hand MD Corp. The Company expensed $120,000 and $40,000 through payroll for the years ended December 31, 2016 and 2015, respectively. As of December 31, 2016 and 2015, the total outstanding balance was $0. On November 12, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for the purchase of NomadChoice Pty Limited and Breakthrough Products, Inc. At December 31, 2016 and 2015, the Company owed Knight $3,680,162 and $3,571,314, respectively, on this loan, net of discount (see Note 12). On December 22, 2016, we issued to Knight Therapeutics (Barbados) Inc., or Knight, 7,500,000 shares of our common stock in exchange for the cancellation of warrants to purchase an aggregate of 8,132,002 shares of our common stock held by Knight, with per share purchase prices of $0.34 and $0.49, and the cancellation of an option to purchase 1,000,000 shares of our common stock held by Knight, with an exercise price of $0.25 per share. As additional consideration, Knight has agreed to purchase up to $2.0 million worth of our common stock if and when we undertake a common stock equity financing, subject to certain terms and conditions. At December 31, 2016 and 2015, NomadChoice Pty Ltd. (subsidiary) of the Company owed Knight Therapeutics $87,678 and $71,573, respectively, in connection with a royalty distribution agreement (see Note 3).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 11 – Accounts Payable and Accrued Liabilities As of December 31, 2016 and 2015, accounts payable and accrued liabilities consisted of the following: December 31, 2016 December 31, 2015 Payroll $ 275,913 $ 128,237 Legal fees 37,546 38,752 Manufacturers 1,459,460 1,527,333 Promotions 1,244,480 1,213,021 Returns allowance 860,126 1,128,133 Customers 401,594 411,033 Interest 31,079 110,754 Royalties 87,677 71,573 Warehousing 19,080 31,748 Others 141,964 371,518 Total $ 4,558,919 $ 5,032,102

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	Note 12 – Notes Payable The Company’s loans payable at December 31, 2016 and 2015 are as follows: December 31, 2016 December 31, 2015 Loans payable $ 7,634,697 $ 12,406,589 Unamortized debt discount - (2,536,419 ) Unamortized debt issuance cost (163,549 ) (378,852 ) Total 7,471,148 9,491,319 Less: Current portion (6,640,903 ) (3,775,669 ) Long-term portion $ 830,245 $ 5,715,650 $6,000,000 January 22, 2015 Loan: On January 22, 2015, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan the Company $6.0 million (the “Loan”), and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring the Focus Factor Business (defined below). At closing, the Company paid Knight an origination fee of $120,000 and a work fee of $60,000 and also paid $40,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year; provided, however, that upon the occurrence of an equity or convertible equity offering by the Company of at least $1.0 million, the interest rate will drop to 13% per year. Interest accrues quarterly and is payable in arrears on March 31, June 30, September 30 and December 31 in each year, beginning on March 31, 2015. All outstanding principal and accrued and unpaid interest is due on the earliest to occur of either January 20, 2017 (the “Maturity Date”), or the date that Knight, in its discretion, accelerates the Company’s obligations due to an event of default. The Company may extend the Maturity Date for two successive additional 12-month periods if at March 31, 2016 and March 31, 2017, respectively, the Company’s revenues exceed $13.0 million and its EBITDA exceeds $2.0 million for the respective 12-month period then ending. These covenants were achieved, therefore the Company chose to extend the loan for the first 12-month period. Principal payments under the Loan Agreement commenced on June 30, 2015 and continue quarterly as set forth on the Repayment Schedule to the Loan Agreement. Subject to certain restrictions, the Company may prepay the outstanding principal of the Loan (in whole but not in part) at any time if the Company pays a concurrent prepayment fee equal to the greater of (i) the total unpaid annual interest that would have been payable during the year in which the prepayment is made if the prepayment is made prior to the first anniversary of the closing, and (ii) $300,000. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in all present and future assets of the Company. The Company also agreed to not pledge or otherwise encumber its intellectual property assets, subject to certain customary exceptions. The Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to the Company’s business and the aggregate consideration to be paid does not exceed $100,000) or make capital expenditures in excess of $100,000 over the Company’s annual business plan in any year. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect default. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of the Loan will bear a default interest rate of an additional 5%. In connection with the Loan Agreement, the Company issued to Knight a warrant that entitled Knight to purchase 4,595,187 shares of common stock of the Company (“Common Stock”) on or prior to close of business on January 30, 2015 (the “ST Warrant”). The aggregate exercise price of the Common Stock under the ST Warrant is $1.00. Knight exercised the ST Warrant on January 22, 2015. Also in connection with the Loan Agreement, the Company issued to Knight a warrant to purchase 3,584,759 shares of Common Stock on or prior to the close of business of January 22, 2025 (the “LT Warrant”). The exercise price per share of the Common Stock under the LT Warrant is $0.34. The LT Warrant provides for cashless exercise. The LT Warrant also provides that in the event the closing price of the Common Stock remains above $1.00 for six consecutive months, Knight will forfeit the difference between the number of shares acquired under the LT Warrant prior to 90 days after such six-month period, and 25% of the shares purchasable under the LT Warrant. The beneficial conversion feature of the warrants issued to the noteholders amounted to $1,952,953 (ST warrants) and $1,462,560 (LT warrants), respectively, and was recorded as debt discount of the corresponding debt. The Company recognized amortization of debt discount of $1,952,953 (ST warrants) and $854,828 (LT warrants) during the year ended December 31, 2015. The Company recognized amortization of debt discount of $607,732 (LT warrants) during the year ended December 31, 2016. Unamortized debt discount as of December 31, 2015 amounted to $607,732. During 2016, this debt discount was fully expensed in conjunction with the cancellation of all warrants and options held by Knight. The Company also recorded deferred financing costs of $289,045 with respect to the above loan. The Company recognized amortization of deferred financing costs of $92,976 and $136,207 during the years ended December 31, 2016 and 2015, respectively. Unamortized debt issuance cost as of December 31, 2016 amounted to $59,861. The Company recognized and paid interest expense of $625,359 and $805,686 during the years ended December 31, 2016 and 2015, respectively. Accrued interest expense was $0 as of both December 31, 2016 and 2015. Loan payable balance was $2,812,500 and $4,875,000 as of December 31, 2016 and 2015, respectively. On December 22, 2016, we entered into Subscription Agreement with Knight Therapeutics (Barbados) Inc., or Knight, and issued 7,500,000 shares of our common stock in exchange for the cancellation of warrants to purchase an aggregate of 8,132,002 shares of our common stock held by Knight, with per share purchase prices of $0.34 and $0.49, and the cancellation of an option to purchase 1,000,000 shares of our common stock held by Knight, with an exercise price of $0.25 per share. As additional consideration, Knight has agreed to purchase up to $2.0 million worth of our common stock if and when we undertake a common stock equity financing, subject to certain terms and conditions. $1,500,000 January 22, 2015 Loan: On January 22, 2015, the Company issued a 0% promissory note in a principal amount of $1,500,000 in connection with an Asset Purchase Agreement (see note 1). The note has a maturity date of January 20, 2017, with $750,000 to be paid on or before January 20, 2016 and an additional $750,000 to be paid on or before January 20, 2017. Loan payable balance was $750,000 and $1,500,000 as of December 31, 2016 and 2015, respectively. The loan was paid in full in January 2017. $950,000 June 26, 2015 Security Agreement: On June 26, 2015, the Company, through its wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000 in connection with an Asset Purchase Agreement (see note 1). The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million. The Company also recorded deferred financing costs of $10,486 with respect to the above agreement. The Company recognized amortization of deferred financing costs of $5,243 and $2,643 during the years ended December 31, 2016 and 2015, respectively. Unamortized debt issuance cost as of December 31, 2016 amounted to $2,600. The Company recorded present value of future payments of $290,947 and $531,589 as of December 31, 2016 and 2015, respectively. The Company recorded interest expense of $59,358 and $37,372 for the year ended December 31, 2016 and 2015, respectively. $5,500,000 November 12, 2015 Loan: On November 12, 2015, we entered into a First Amendment to Loan Agreement (“First Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $5.5 million, and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring Breakthrough Products, Inc. and NomadChoice Pty Limited through Stock Purchase Agreements. At closing, we paid Knight an origination fee of $110,000 and a work fee of $55,000 and also paid $24,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year. The interest rate will decrease to 13% if we meet certain equity-fundraising targets. The New Loan Agreement matures on November 11, 2017. In connection with the New Loan Agreement, we issued Knight a warrant that entitles Knight to purchase 5,550,625 shares of our common stock (“Knight Warrant Shares”) representing approximately 6.5% of our fully diluted capital, which Knight exercised in full on November 12, 2015. Knight also received a 10-year warrant entitling Knight to purchase up to 4,547,243 shares of our common stock at $0.49 per share (“Knight Warrants”). The beneficial conversion feature of the warrants issued to the noteholders amounted to $2,553,287 (5,550,625 warrants) and $2,067,258 (4,547,243 warrants), respectively, and was recorded as debt discount of the corresponding debt. For derivative liability calculation on 4,547,243 warrants, refer to Note 17. The Company recognized amortization of debt discount of $2,553,287 (5,550,625 warrants) and $138,571 (4,547,243 warrants) during the year ended December 31, 2015. The Company recognized amortization of debt discount of $1,012,419 (4,547,243 warrants) during the year ended December 31, 2016 and remaining balance of $916,267 was extinguished as part of the Subscription Agreement disclosed below. Unamortized debt discount as of December 31, 2015 amounted to $1,928,686. During 2016, this debt discount of $1,012,419 was expensed and $912,267 was extinguished in conjunction with the cancellation of all warrants and options held by Knight. The Company also recorded deferred financing costs of $233,847 with respect to the above loan. The Company recognized amortization of deferred financing costs of $117,083 and $15,675 during the years ended December 31, 2016 and 2015, respectively. Unamortized debt issuance cost as of December 31, 2016 amounted to $101,088. The Company recognized interest expense of $767,904 and $110,753 during the years ended December 31, 2016 and 2015, respectively. Accrued interest expense was $31,079 and $110,753 as of December 31, 2016 and 2015, respectively. The principal balance outstanding at December 31, 2016 and 2015 was $3,781,250 and $5,500,000, respectively. On December 22, 2016, we entered into Subscription Agreement with Knight Therapeutics (Barbados) Inc., or Knight, and issued 7,500,000 shares of our common stock in exchange for the cancellation of warrants to purchase an aggregate of 8,132,002 shares of our common stock held by Knight, with per share purchase prices of $0.34 and $0.49, and the cancellation of an option to purchase 1,000,000 shares of our common stock held by Knight, with an exercise price of $0.25 per share. As additional consideration, Knight has agreed to purchase up to $2.0 million worth of our common stock if and when we undertake a common stock equity financing, subject to certain terms and conditions.

Stockholders_ Deficit

Stockholders’ Deficit	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders’ Deficit	Note 13 – Stockholders’ Deficit The total number of shares of all classes of capital stock which the Company is authorized to issue is 75,000,000 shares of common stock with $0.00001 par value. On July 30, 2014, the Company’s board of directors approved an increase of the Company’s authorized common stock from 75,000,000 to 300,000,000 shares, which increase was approved by the Company’s shareholders and became effective on August 5, 2015. On April 17, 2014, upon approval from FINRA, the Company effected a 30 for 1 forward stock split by way of a stock dividend, of all of its issued and outstanding shares of common stock (the “Stock Split”). The Stock Split did not affect the number of the Company’s authorized common stock or its par value. All references in the accompanying consolidated financial statements and notes thereto have been retroactively restated to reflect the stock split. During the year ended December 31, 2015, the Company issued 4,595,187 shares of its common stock upon exercise of the ST Warrant at an aggregate exercise price of $1.00 in connection with the Loan Agreement (see note1). During the year ended December 31, 2015, the Company issued 5,550,625 shares of its common stock upon exercise of a Warrant at an aggregate exercise price of $1.00 in connection with the Loan Agreement (see note1). During the year ended December 31, 2015, the Company issued 400,000 shares of its common stock to a note holder in a note conversion at $0.25 per share. At the time of conversion, the note was valued at $100,000 for outstanding principal. During the year ended December 31, 2015, the Company issued 2,142,857 shares of its common stock valued at $0.70 per share in accordance with Contribution Agreement entered into with Hand MD Corp. in exchange for 50% of Hand MD Corp.’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 3,571,428 shares of its common stock valued at $0.35 per share in accordance with a stock purchase agreement entered into with NomadChoice Pty Limited in exchange for 100% of NomadChoice Pty Limited’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 3,000,000 shares of its common stock valued at $0.85 per share in accordance with a stock purchase agreement entered into with Breakthrough Products, Inc. in exchange for 100% of Breakthrough Product Inc.’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 40,000 shares of its common stock valued at $0.65 per share for cash. During the year ended December 31, 2015, the Company issued 292,857 shares of its common stock valued at $0.70 per share to settle accounts payable. As of December 31, 2015, the Company committed to issue common stock valued at $68,000 for services rendered. During 2016, 213,742 shares of the Company’s common stock were issued valued at $0.32 per share. During the year ended December 31, 2016, the Company issued 71,248 shares of its common stock valued at $0.70 per share for services rendered. During the year ended December 31, 2016, the Company cancelled 713,767 shares of its common stock valued at $125,000 in conjunction with an agreement with a former shareholder. The Company committed to issue 125,000 shares to former shareholders valued at $56,250 recorded as settlement expense during the year. These shares were not issued as of the date of this Annual Report. During the year ended December 31, 2016, the Company issued 7,500,000 shares of its common stock valued at $1,456,492 in conjunction with an agreement to cancel all outstanding stock warrants and options issued along with the loans payable. As of December 31, 2016 and 2015, there were 88,764,357 and 81,692,954 shares of the Company’s common stock issued and outstanding, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Litigation: From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations. Operating leases In April 2014, a subsidiary entered into an extension of a non-cancellable operating lease for office space that expires on March 31, 2017. Rent expense under this lease for the period from acquisition until December 31, 2015 was $8,923 per month less a $3,010 per month sublease through March 2017. In December 2015, a subsidiary entered into a non-cancellable operating lease for office space through November 2016. This lease was extended until April 2017. Rental payments under this lease are $5,900 Australian dollars per month, which is approximately $4,480. In December 2015, the Company entered into a non-cancellable operating lease for office space through December 2016. Rental payments under this lease were $5,500 per month. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: Year ending December 31: 2017 $ 35,659 Total $ 35,659 On December 8, 2014, a subsidiary entered into a non-cancellable 36 month phone lease with an estimated cost of $894 a month. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: Year ending December 31: 2017 $ 9,834 Total $ 9,834

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	Note 15 – Stock Options On July 30, 2014, the Company’s board of directors approved the Company’s 2014 Equity Incentive Plan and the reservation of 15,525,000 shares of common stock for issuance under such plan. Such plan was approved by the Company’s shareholders and became effective on August 5, 2015. On April 2, 2014, the Company granted 1,000,000 options with an exercise price of $0.25 per share to the Company owned by Mr. Jack Ross, Chief Executive Officer of the Company. On December 14, 2015, the Company granted 1,000,000 options each with an exercise price of $0.25 per share to two Board Members of the Company. On December 14, 2015, the Company granted 1,000,000 options each with an exercise price of $0.65 per share to two employees of the Company. On December 14, 2015, the Company granted 1,000,000 options with an exercise price of $0.25 per share to a Board Observer of the Company. During 2016, these options were cancelled in conjunction with the issuance of 7,500,000 shares and the cancellation of all outstanding options and warrants. On February 18, 2016, the Company granted 300,000 options with an exercise price of $0.70 per share to an employee of the Company. On April 18, 2016, the Company granted 500,000 options with an exercise price of $0.70 per share to an employee of the Company. On July 4, 2016, the Company granted 500,000 options with an exercise price of $0.70 per share to an employee of the Company. The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2016: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.25 - $0.70 6,300,000 6.5 $ 0.47 3,408,333 $ 0.38 The stock option activity for the year ended December 31, 2016 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 1,000,000 $ 0.25 Granted 4,000,000 0.45 Exercised - - Expired or canceled - - Outstanding at December 31, 2015 5,000,000 $ 0.41 Granted 2,300,000 0.50 Exercised - - Expired or canceled (1,000,000 ) (0.25 ) Outstanding at December 31, 2016 6,300,000 $ 0.47 Stock-based compensation expense related to vested options was $2,200,160 and $523,714 during the years ended December 31, 2016 and 2015, respectively. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2015 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.74, risk-free interest rate of 2.23%, volatility of 154%, expected lives of 10 years, and dividend yield of 0%. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2016 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.40-0.61, risk-free interest rate of 0.90-1.24%, volatility of 135-160%, expected lives of 3-6 years, and dividend yield of 0%. Stock options outstanding as of December 31, 2016, as disclosed in the above table, have an intrinsic value of $780,000.

Stock Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2016
Stock Warrants
Stock Warrants	Note 16 – Stock Warrants The following table summarizes the warrants outstanding and the related prices for the shares of the Company’s common stock at December 31, 2016: Warrants Outstanding Warrants Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) 5.00 1,000,000 1.96 5.00 1,000,000 5.00 The warrant activity for the year ended December 31, 2016 is as follows: Warrants Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 - $ - Granted 19,277,814 0.44 Exercised (10,415,812 ) 0.00000020 Expired or canceled - - Outstanding at December 31, 2015 9,132,002 $ 0.92 Granted - - Exercised - - Expired or canceled (8,132,002 ) (0.42 ) Outstanding at December 31, 2016 1,000,000 $ 5

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Note 17 – Derivatives The Company has incurred a liability for the estimated fair value of a derivative warrant instrument. The estimated fair value of the derivative warrant instruments has been calculated using the Black-Scholes fair value option-pricing model with key input variables provided by management, as of the issue date, with the valuation offset against additional paid in capital, and at each reporting date, with changes in fair value recorded as gains or losses on revaluation in non-operating income (expense). The Company identified embedded derivatives related to the warrants issued along with loan payable entered into in November 2015. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the warrants and to adjust the fair value as of each subsequent balance sheet date. At the inception of the warrants, the Company determined a fair value of $2,067,258 of the embedded derivative. The fair value of the embedded derivative was determined using the Black-Scholes Model based on the following assumptions: November 12, 2015 Risk-free interest rate 2.32 % Expected remaining term 10 Years Expected volatility 157.56 % Dividend yield 0 % The initial fair values of the embedded derivative of $2,067,258 was allocated as a debt discount $2,067,258. Fair value at December 31, 2015 was estimated to be $3,096,179 and based on the following assumptions: December 31, 2015 Risk-free interest rate 2.27 % Expected remaining term 9.75 Years Expected volatility 152.07 % Dividend yield 0 % During the year ended December 31, 2015, the increase in the fair value of the warrant derivative liability of $1,028,921 was recorded as a loss on change in fair value of derivative liability. During the year ended December 31, 2016, the decrease in the fair value of the warrant derivative liability of $1,380,600 was recorded as a gain on change in fair value of derivative liability. During December 2016, the Company cancelled these warrants and issued 7,500,000 shares of common stock and accordingly warrant derivative liability was extinguished. Fair value at December 23, 2016 when the warrants were cancelled was estimated to be $1,715,579, based on the following assumptions: December 23, 2016 Risk-free interest rate 2.55 % Expected remaining term 8.92 Years Expected volatility 143.15 % Dividend yield 0 % The following table summarizes the derivative liabilities included in the balance sheet at December 31, 2016: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance - December 31, 2015 $ 3,096,179 Extinguishment of derivatives liabilities from cancellation of warrants (1,715,579 ) Gain on change in fair value of the derivative liabilities (1,380,600 ) Balance – December 31, 2016 $ -

Segments

Segments	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segments	Note 18 – Segments Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. Net sales attributed to customers in the United States and foreign countries for the years ended December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 United States $ 32,010,018 $ 13,129,753 Foreign countries 2,830,376 326,624 $ 34,840,394 $ 13,456,377 The Company’s net sales by product group for the years ended December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 Nutraceuticals $ 33,877,529 $ 13,030,006 Over the Counter (OTC) 907,401 416,417 Cosmeceuticals 55,464 9,954 $ 34,840,394 $ 13,456,377 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales. Long-lived assets (net) attributable to operations in the United States and foreign countries as of December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 United States $ 13,174,461 $ 17,411,598 Foreign countries 21,599 12,081 $ 13,196,060 $ 17,423,679

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events Other than disclosed below, management evaluated all activities of the Company through the issuance date of the Company’s consolidated financial statements and concluded that no subsequent events have occurred that would require adjustments or disclosure into the consolidated financial statements. During 2017, the Company paid the remaining $750,000 on the loan to Factor Nutrition Labs, bringing the balance to $0. The Company also paid an additional $1,031,250 in principal on the second loan to Knight Therapeutics.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2016 and 2015 significant estimates included are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, impairment analysis of goodwill and intangible assets, estimates used in the fair value calculation of stock based compensation, beneficial conversion feature and derivative liability on warrants using Black-Scholes Model.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2016 and 2015 the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2016 and 2015, the uninsured balances amounted to$2,038,985 and $3,453,290, respectively.
Capitalization of Fixed Assets	Capitalization of Fixed Assets The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit.
Accounts Receivable	Accounts receivable Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of December 31, 2016 and 2015, allowance for doubtful accounts was $0 and $121,291, respectively.
Advertising Expense	Advertising Expense The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling and marketing expense in the accompanying consolidated statements of operations.
Research and Development	Research and Development Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred.
Income Taxes	Income Taxes The Company utilizes FASBASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) Per Common Share The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of December 31, 2016 and 2015, options to purchase 6,300,000 and 5,000,000 shares of common stock, respectively, were outstanding. As of December 31, 2016 and 2015, warrants to purchase 1,000,000 and 9,132,002 shares of common stock, respectively, were outstanding. These potential shares were excluded from the shares used to calculate diluted loss per share as their inclusion would reduce net loss per share.
Going Concern	Going Concern The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at December 31, 2016 of $9,366,000. The Company had a working capital deficit of $4,944,587 as of December 31, 2016. During the year ended December 31, 2016, the Company incurred net loss of $796,161. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs and has income from operations of $2,933,585. The ability of the Company to continue as a going concern is dependent on the Company continuing to execute the sales of their products. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Fair Value Measurements	Fair Value Measurements The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure. ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 - Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2016, the Company has determined that there were no assets or liabilities measured at fair value.
Inventory	Inventory Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items.
Stock-Based Compensation	Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Intangible Assets with Indefinite Lives	Intangible Assets with Indefinite Lives We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization except intellectual property of $1,450,000 acquired as part of Asset Purchase Agreement entered into with Factor Nutrition LLC on January 22, 2015. As of December 31, 2016 and 2015, our qualitative analysis of intangible assets with indefinite lives did not indicate any impairment.
Long-lived Assets	Long-lived Assets Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of December 31, 2015, our qualitative analysis of long-lived assets did not indicate any impairment. However, as of December 31, 2016 our review of intangible assets related to one of our subsidiaries did indicate that the carrying amount of the asset may not be recoverable. During the year ended December 31, 2016, the Company fully impaired related intangible assets and charged to operations impairment loss of $193,750.
Goodwill	Goodwill An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of December 31, 2015 our qualitative analysis of goodwill did not indicate any impairment. However, as of December 31, 2016, our review of Goodwill related to one of our subsidiaries did indicate that the carrying amount of the asset may not be recoverable. During the year ended December 31, 2016, the Company fully impaired related goodwill and charged to operations impairment loss of $1,983,160.
Foreign Currency Translation	Foreign Currency Translation The functional currency of one of the Company’s foreign subsidiaries (Nomadchoice Pty Ltd.) is the U.S. Dollar. The Company’s subsidiary maintains its record using local currency (Australian Dollar). All monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at fiscal year-end exchange rates, non-monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as remeasurement gain or loss on translation of foreign subsidiary. The functional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income. Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred.
Concentrations of Credit Risk	Concentrations of Credit Risk In the normal course of business, the Company provides credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns.
Warehousing Costs	Warehousing costs Warehouse costs include all third party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales.
Product Display Costs	Product display costs All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred.
Warrant Derivative Liabilities	Warrant Derivative Liabilities ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. A Black-Scholes-Merton option-pricing model, with dilution effects, was utilized to estimate the fair value of the Warrant Derivative Liabilities as of November 12, 2015 and December 31, 2015. As of December 23, 2016 the Warrant Derivative Liability was extinguished in conjunction with the issuance of shares. This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 December 23, 2016 Stock Price $ 0.46 $ 0.69 $ 0.39 Exercise Price $ 0.49 $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 8.92 Stock Volatility 157.56 % 152.07 143.15 % Risk-Free Rate 2.32 % 2.27 2.55 % Dividend Rate 0 % 0 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243 4,547,243
Cost of Sales	Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt facilities.
Shipping Costs	Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses.
Related Parties	Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties shall be recorded at fair value of the goods or services exchanged.
Segment Reporting	Segment Reporting Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.
Reclassification of Prior Period Presentation	Reclassification of Prior Period Presentation Certain reclassifications have been made to conform the prior period data to the current presentations. These reclassifications had no effect on the reported results.
Recent Accounting Pronouncements	Recent Accounting Pronouncements ASU 2016-18 In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), which requires that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently evaluating the impact of adopting ASU 2016-18 on our consolidated financial statements. ASU 2016-15 In August 2016, the FASB issued AS 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The effective date for ASU 2016-15 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently evaluating the impact of adopting ASU 2016-18 on our consolidated financial statements. ASU 2016-10 In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-10 on its consolidated financial statements. ASU 2016-09 In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation, or ASU No. 2016-09. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements. ASU 2016-08 In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its consolidated financial statements. ASU 2016-01 In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. ASU 2015-17 In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. Currently deferred taxes for each tax jurisdiction are presented as a net current asset or liability and net noncurrent asset or liability on the balance sheet. To simplify the presentation, the new guidance requires that deferred tax liabilities and assets for all jurisdictions along with any related valuation allowances be classified as noncurrent in a classified statement of financial position. This guidance is effective for interim and annual reporting periods beginning after December 15, 2016, and early adoption is permitted. The Company adopted this guidance in the fourth quarter of the year ended December 31, 2015 on a retrospective basis. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements., and did not have any effect on prior periods due to the full valuation allowance against the Company’s net deferred tax assets. ASU 2015-16 In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement –Period Adjustments. Changes to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and, instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for both public and private companies for periods beginning after December 15, 2015. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2015-14 In August 2015, the FASB issued ASU No. 2015-14, Revenue From Contracts With Customers (Topic 606). The amendments in this ASU defer the effective date of ASU 2014-09. Public business entities should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are still evaluating the effect of the adoption of ASU 2014-09 on our consolidated financial statements. ASU 2015-11 In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out (“LIFO”) method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. We do not expect the adoption of ASU 2015-11 to have a material effect on our consolidated financial statements. ASU 2015-05 In April 2015, the FASB issued ASU 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40). ASU 2015-05 provides guidance regarding the accounting for a customer’s fees paid in a cloud computing arrangement; specifically about whether a cloud computing arrangement includes a software license, and if so, how to account for the software license. ASU 2015-05 is effective for public companies’ annual periods, including interim periods within those fiscal years, beginning after December 15, 2015 on either a prospective or retrospective basis. Early adoption is permitted. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2015-07 In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent) This guidance eliminates the requirement to categorize investments within the fair value hierarchy if their fair value is measured using the net asset value (“NAV”) per share practical expedient in the FASB’s fair value measurement guidance. The new standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements ASU 2015-03 In April 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. The Company reclassified debt issuance cost of $160,950 and $378,852 from other assets to liabilities and netted off with the related loans in the liabilities as of December 31, 2016 and 2015, respectively. ASU 2015-02 In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2015-01 In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2014-17 In November 2014, the FASB issued ASU No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting.” This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows. ASU 2014-16 In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not currently have issued, nor are we investors in, hybrid financial instruments. Adoption of this new standard did not have any impact on the Company’s financial position, results of operations or cash flows. ASU 2014-15 In August 2014, the FASB issued ASU No. 2014-15 Presentation of Financial Statements-Going Concern. The amendments in this update apply to all reporting entities and require an entity’s management, in connection with preparing financial statements for each annual and interim reporting period, to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for annual periods ending after December 15, 2016. We adopted this standard for the year ended December 31, 2016. Based on the results of our analysis, no additional disclosures were required. ASU 2014-12 In June 2014, the FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Adoption of this new standard did not have any impact on the Company’s financial position, results of operations or cash flows. ASU 2014-09 In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are still evaluating the effect of the adoption of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year for all entities and permits early adoption on a limited basis. ASU 2014-09 will be effective for the Company in the first quarter of 2018, and early adoption permitted in the first quarter of 2017. We are still evaluating the effect of the adoption of ASU 2014-09 on our consolidated financial statements. ASU 2014-08 In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) and Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” ASU 2014-08 amends the definition for what types of asset disposals are to be considered discontinued operations, as well as amending the required disclosures for discontinued operations and assets held for sale. ASU 2014-08 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014. The adoption of ASU 2014-08 did not have any effect on our financial position, results of operations or cash flows. There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed financial position, results of operations or cash flows.
Change in Fiscal Year End	Change in Fiscal Year End On April 21, 2014, the Company’s board of directors approved a change to the Company’s fiscal year end from July 31 to December 31 of each year.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Assumptions Used for Fair Value of Warrant Derivative Liabilities	This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 December 23, 2016 Stock Price $ 0.46 $ 0.69 $ 0.39 Exercise Price $ 0.49 $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 8.92 Stock Volatility 157.56 % 152.07 143.15 % Risk-Free Rate 2.32 % 2.27 2.55 % Dividend Rate 0 % 0 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243 4,547,243

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Purchase Price Allocated to Acquisition of Assets	The purchase price allocated to the acquisition of the assets of Factor Nutrition Labs, LLC is made up as follows: Amount Cash payment made on January 22, 2015 $ 4,500,000 Cash payment made on January 20, 2016 750,000 Cash payment to be made on January 20, 2017 750,000 Total $ 6,000,000
TPR Investments Pty Ltd [Member]
Purchase Price Allocated to Acquisition of Assets	The purchase price allocated to the acquisition of the assets of NomadChoice is made up as follows: Cash $ 2,848,800 Stock issued at closing 1,750,000 Earn-out payment 2,496,900 Total $ 7,095,700
Distribution Option Agreement One [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts receivable $ 2,733,167 Inventory 67,113 Intellectual property 1,000,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 2,071,517 Liabilities Accounts payable (971,381 ) Accrued expenses (941,446 ) $ 6,000,000
Distribution Option Agreement Two [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Accounts receivable $ 2,733,167 Inventory 67,113 Intellectual property 1,450,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 1,621,517 Liabilities Accounts payable (971,381 ) Accrued expenses (941,446 ) $ 6,000,000
Security Agreement [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts receivable $ 58,054 Inventory 204,925 Intangible property 100,000 License agreement 606,553 Liabilities Accounts payable (51,795 ) Accrued expenses (148,520 ) $ 769,217
Contribution Agreement [Member] | Hand MD Corp [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Intangible property $ 100,000 License agreement 1,670,675 Liabilities - Royalty payable (258,897 ) Others (11,778 ) $ 1,500,000
Stock Purchase Agreement One [Member] | Breakthrough Products, Inc [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 2,298,619 Accounts receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 3,253,160 Liabilities Accounts payable (741,822 ) Accrued expenses (2,202,848 ) $ 2,980,411
Purchase Price Allocated to Acquisition of Assets	The preliminary purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 2,550,000 Stock warrants issued 430,411 Total $ 2,980,411
Stock Purchase Agreement One [Member] | TPR Investments Pty Ltd [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 1,584,642 Other receivable 30,684 Inventory 134,212 Prepaid expenses 141,070 Fixed assets, net 5,698 Intangible assets, Net 3,493 Blogger database 200,000 Customer database 500,000 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 6,174,899 Liabilities Accounts payable (77,064 ) Accrued expenses (56,224 ) Dividends payable (1,177,152 ) Provision for income tax (518,558 ) $ 7,095,700
Stock Purchase Agreement Two [Member] | Breakthrough Products, Inc [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Cash $ 2,298,619 Accounts receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 250,000 Non-compete provision - Goodwill 1,983,160 Liabilities Accounts Payable (741,822 ) Accrued Expenses (2,202,848 ) $ 1,810,411
Purchase Price Allocated to Acquisition of Assets	The adjusted purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 1,380,000 Stock warrants issued 430,411 Total $ 1,810,411
Stock Purchase Agreement Two [Member] | TPR Investments Pty Ltd [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed On Estimated Fair Values	The final allocation of the purchase price to the assets acquired and liabilities assumed based on the independent valuation is as follows: Assets Cash $ 1,584,642 Other receivable 30,684 Inventory 134,212 Prepaid expenses 141,070 Fixed assets, net 5,698 Intangible assets, Net 3,493 Blogger database 85,000 Customer database 715,000 Intellectual property - Non-compete provision 50,000 Goodwill 6,174,899 Liabilities Accounts payable (77,064 ) Accrued expenses (56,224 ) Dividends payable (1,177,152 ) Provision for income tax (518,558 ) $ 7,095,700

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The table below summarizes the differences between the U.S. statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2016 and 2015: December 31, 2016 December 31, 2015 U.S. Statutory Rate 34 % 34 % U.S. effective rate in excess of AU/CA rate (1 )% (1 )% U.S. valuation allowance (34 )% (34 )% Foreign Tax - Australia 638 % 6.8 % Total provision for income taxes 637 % 5.8 %
Schedule of Deferred Income Tax Assets	The Company has deferred tax assets, which have been fully reserved, as follows as of December 31, 2016 and 2015: December 31, 2016 December 31, 2015 Deferred tax assets $ 12,950,124 $ 11,460,536 Valuation allowance for deferred tax assets (12,950,124 ) (11,460,536 ) Net deferred tax assets $ - $ -

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable, Net of Allowances for Sales Returns and Doubtful Accounts	Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following: December 31, 2016 December 31, 2015 Trade accounts receivable $ 2,195,391 $ 4,101,148 Less allowances - (121,291 ) Total accounts receivable, net $ 2,195,391 $ 3,979,857

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of Prepaid Expenses	At December 31, 2016 and 2015, prepaid expenses consisted of the following: December 31, 2016 December 31, 2015 Advances for inventory $ 188,980 $ 171,494 Media production 207,555 55,849 Insurance 70,392 54,519 Trade shows 46,700 45,700 Deposits 6,228 41,228 Consultants 15,000 24,000 Rent 15,452 16,216 Promotion - Bloggers 426,220 - License agreement 258,333 - Software subscriptions 88,782 - Miscellaneous 24,960 13,428 Total $ 1,348,602 $ 422,434

Concentration of Credit Risk (T

Concentration of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Summary of Major Suppliers	For the year ended December 31, 2016 and 2015, our products were made by the following suppliers: FOCUSfactor Atrium Innovations - Pittsburgh, PA Vit-Best Nutrition, Inc. - Tustin, CA Flat Tummy Tea Caraway Tea Company, LLC - Highland, NY - Neuragen C-Care, LLC - Linthicum Heights, MD - UrgentRx Capstone Nutrition - Ogden, UT - Hand MD HealthSpecialty - Santa Fe Springs, CA

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Carrying Value of Inventory	The carrying value of inventory consisted of the following: December 31, 2016 December 31, 2015 Finished goods $ 474,420 $ 535,908 Components 431,241 115,340 Inventory in transit 104,500 - Raw Materials 92,616 35,406 Total inventory $ 1,102,777 $ 686,654

Fixed Assets and Intangible A34

Fixed Assets and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Assets
Summary of Fixed and Intangible Assets	As of December 31, 2016 and 2015, fixed assets and intangible assets consisted of the following: December 31, 2016 December 31, 2015 Property and equipment $ 308,084 $ 18,187 Less accumulated depreciation (50,698 ) (6,170 ) Fixed assets, net $ 257,386 $ 12,017 Depreciation expense for the years ended December 31, 2016 and 2015 was $44,480 and $1,513, respectively. December 31, 2016 December 31, 2015 FOCUSfactor intellectual property $ 1,450,000 $ 1,000,000 Intangible assets subject to amortization 5,373,017 5,521,751 Less accumulated amortization and impairment (1677,583 ) (606,489 ) Intangible assets, net $ 5,145,434 $ 5,915,262
Summary of Estimated Aggregate Amortization Expense	The estimated aggregate amortization expense over each of the next five years is as follows: 2017 $ 1,074,650 2018 1,074,576 2019 1,074,311 2020 471,897 2021 -

Accounts Payable and Accrued 35

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As of December 31, 2016 and 2015, accounts payable and accrued liabilities consisted of the following: December 31, 2016 December 31, 2015 Payroll $ 275,913 $ 128,237 Legal fees 37,546 38,752 Manufacturers 1,459,460 1,527,333 Promotions 1,244,480 1,213,021 Returns allowance 860,126 1,128,133 Customers 401,594 411,033 Interest 31,079 110,754 Royalties 87,677 71,573 Warehousing 19,080 31,748 Others 141,964 371,518 Total $ 4,558,919 $ 5,032,102

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Loan Payable	The Company’s loans payable at December 31, 2016 and 2015 are as follows: December 31, 2016 December 31, 2015 Loans payable $ 7,634,697 $ 12,406,589 Unamortized debt discount - (2,536,419 ) Unamortized debt issuance cost (163,549 ) (378,852 ) Total 7,471,148 9,491,319 Less: Current portion (6,640,903 ) (3,775,669 ) Long-term portion $ 830,245 $ 5,715,650

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Future Minimum Rental Payments For Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: Year ending December 31: 2017 $ 35,659 Total $ 35,659
Subsidiary [Member]
Schedule of Future Minimum Rental Payments For Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: Year ending December 31: 2017 $ 9,834 Total $ 9,834

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Options Outstanding by Price Range	The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2016: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.25 - $0.70 6,300,000 6.5 $ 0.47 3,408,333 $ 0.38
Schedule of Stock Options Activity	The stock option activity for the year ended December 31, 2016 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 1,000,000 $ 0.25 Granted 4,000,000 0.45 Exercised - - Expired or canceled - - Outstanding at December 31, 2015 5,000,000 $ 0.41 Granted 2,300,000 0.50 Exercised - - Expired or canceled (1,000,000 ) (0.25 ) Outstanding at December 31, 2016 6,300,000 $ 0.47

Stock Warrants (Tables)

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Stock Warrants
Summary of Warrants Outstanding, Warrant Exercisability and Related Prices for Shares of Common Stock	The following table summarizes the warrants outstanding and the related prices for the shares of the Company’s common stock at December 31, 2016: Warrants Outstanding Warrants Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) 5.00 1,000,000 1.96 5.00 1,000,000 5.00
Schedule of Stock Warrants Activity	The warrant activity for the year ended December 31, 2016 is as follows: Warrants Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 - $ - Granted 19,277,814 0.44 Exercised (10,415,812 ) 0.00000020 Expired or canceled - - Outstanding at December 31, 2015 9,132,002 $ 0.92 Granted - - Exercised - - Expired or canceled (8,132,002 ) (0.42 ) Outstanding at December 31, 2016 1,000,000 $ 5

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Assumptions Used for Fair Value of Derivative	The fair value of the embedded derivative was determined using the Black-Scholes Model based on the following assumptions: November 12, 2015 Risk-free interest rate 2.32 % Expected remaining term 10 Years Expected volatility 157.56 % Dividend yield 0 % December 31, 2015 Risk-free interest rate 2.27 % Expected remaining term 9.75 Years Expected volatility 152.07 % Dividend yield 0 % December 23, 2016 Risk-free interest rate 2.55 % Expected remaining term 8.92 Years Expected volatility 143.15 % Dividend yield 0 %
Summarizes Derivative Liabilities	The following table summarizes the derivative liabilities included in the balance sheet at December 31, 2016: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance - December 31, 2015 $ 3,096,179 Extinguishment of derivatives liabilities from cancellation of warrants (1,715,579 ) Gain on change in fair value of the derivative liabilities (1,380,600 ) Balance – December 31, 2016 $ -

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Summary of Net Sales Attributed to Customers Geographical Segment	Net sales attributed to customers in the United States and foreign countries for the years ended December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 United States $ 32,010,018 $ 13,129,753 Foreign countries 2,830,376 326,624 $ 34,840,394 $ 13,456,377
Summary of Net Sales Attributed to Customers Product Group	The Company’s net sales by product group for the years ended December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 Nutraceuticals $ 33,877,529 $ 13,030,006 Over the Counter (OTC) 907,401 416,417 Cosmeceuticals 55,464 9,954 $ 34,840,394 $ 13,456,377 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales.
Summary of Long-lived Assets (Net) Attributable to Operations Geographical Segment	Long-lived assets (net) attributable to operations in the United States and foreign countries as of December 31, 2016 and 2015 were as follows: December 31, 2016 December 31, 2015 United States $ 13,174,461 $ 17,411,598 Foreign countries 21,599 12,081 $ 13,196,060 $ 17,423,679

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)Segmentshares	Dec. 31, 2015USD ($)shares	Jan. 22, 2015USD ($)
Cash equivalents
Cash federally insured limit per bank	250,000
Cash uninsured amount	2,038,985	3,453,290
Allowance for doubtful accounts	$ 0	121,291
Percentage of valuation allowance	100.00%
Accumulated deficit	$ 9,366,000	8,569,841
Working capital deficit	4,944,587
Net loss	(796,161)	(7,536,548)
Income from operations	2,933,585	486,023
Intangible assets and charged to operations impairment loss	193,750
Goodwill and charged to operations impairment loss	$ 1,983,160
Number of operating segment | Segment	1
Accounting Standards Update 2015-03 [Member]
Reclassified debt issuance cost	$ 160,950	$ 378,852
Options to Purchase of Common Stock [Member]
Anti-dilutive securities | shares	6,300,000	5,000,000
Warrants to Purchase of Common Stock Outstanding [Member]
Anti-dilutive securities | shares	1,000,000	9,132,002
Factor Nutrition LLC [Member]
Value of intellectual property acquired			$ 1,450,000

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Schedule of Assumptions Used for Fair Value of Warrant Derivative Liabilities (Details) - Warrant Derivative Liabilities [Member] - $ / shares	Dec. 23, 2016	Nov. 12, 2015	Dec. 31, 2015
Stock Price	$ 0.39	$ 0.46	$ 0.69
Exercise Price	$ 0.49	$ 0.49	$ 0.49
Expected Life (in years)	8 years 11 months 1 day	10 years	9 years 9 months
Stock Volatility	143.15%	157.56%	152.07%
Risk-Free Rate	2.55%	2.32%	2.27%
Dividend Rate	0.00%	0.00%	0.00%
Outstanding Shares of Common Stock	4,547,243	4,547,243	4,547,243

Acquisitions (Details Narrative

Acquisitions (Details Narrative)

Jun. 30, 2016USD ($)

Jan. 20, 2016USD ($)

Dec. 17, 2015$ / sharesshares

Dec. 03, 2015

Nov. 15, 2015AUDshares

Nov. 12, 2015USD ($)shares

Aug. 18, 2015USD ($)$ / sharesshares

Jun. 26, 2015USD ($)

Jan. 22, 2015USD ($)

Mar. 31, 2016USD ($)

Jun. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 22, 2016$ / shares

Aggregate purchase price of business

$ 4,500,000

Interest expense recorded

(1,567,867)

$ (958,740)

Number of shares contibuted | shares

40,000

Capital stock per share | $ / shares

$ 0.65

Intangible assets, net

5,145,434

$ 5,915,262

Goodwill

7,793,240

11,496,402

Impairment loss

193,750

0

Knight Therapeutics Inc [Member]

Aggregate purchase price of business

$ 1,200,000

Amount payable under the purchase agreement

$ 250,000

$ 250,000

$ 700,000

Total payments of acquire assets

1,200,000

Present value of future payments

290,947

531,589

Interest expense recorded

$ 59,358

37,372

Interest rate percentage

10.00%

Knight Therapeutics Inc [Member] | Security Agreement [Member]

Amortization expense

$ 141,311

70,655

Estimated useful lives of intangible property

5 years

Knight Therapeutics Inc [Member] | Maximum [Member]

Capital stock per share | $ / shares

$ 0.49

Knight Therapeutics Inc [Member] | Minimum [Member]

Capital stock per share | $ / shares

$ 0.34

Knight Therapeutics Inc [Member] | U.S [Member]

Percentage of sale revenue net

2.00%

Knight Therapeutics Inc [Member] | U.S [Member] | Maximum [Member]

Net sales

$ 12,500

Percentage of sale revenue net

5.00%

Hand MD LLC [Member]

Number of shares contibuted | shares

2,142,857

Common stock percentage

50.00%

50.00%

Capital stock per share | $ / shares

$ 0.70

Inventory purchase

$ 106,000

Present value of future royalty payments

$ 313,752

258,897

Hand MD LLC [Member] | License Agreement [Member]

Sales percentage

5.00%

Percentage of amount recevied from sublicensess

5.00%

Hand MD LLC [Member] | License Agreement [Member] | Second Year [Member]

Present value of future royalty payments

$ 250,000

Hand MD LLC [Member] | License Agreement [Member] | Thired Year [Member]

Present value of future royalty payments

500,000

Hand MD LLC [Member] | Consulting Agreement [Member]

Amortization expense

$ 354,135

118,045

Estimated useful lives of intangible property

5 years

Consulting fee paid

$ 10,000

Breakthrough Products, Inc [Member] | Stock Purchase Agreement [Member]

Sales percentage

5.00%

Net sales

$ 5,000,000

Number of shares contibuted | shares

6,000,000

Breakthrough Products, Inc [Member] | Settlement Agreement [Member]

Number of shares contibuted | shares

3,000,000

Capital stock per share | $ / shares

$ 5

Warrant exercise price | $ / shares

$ 0.001

Knight [Member]

Sales percentage

60.00%

UrgentRx Sellers [Member]

Intangible assets, net

$ 193,750

Goodwill

1,983,160

Impairment loss

2,176,910

UrgentRx Sellers [Member] | Breakthrough Products, Inc [Member]

Amortization expense

$ 51,667

4,583

Estimated useful lives of intangible property

5 years

Increase decrease in intangible assets

$ 150,000

Decreased additional paid in capital and goodwill

1,170,000

UrgentRx Sellers [Member] | Breakthrough Products, Inc [Member] | Non-Compete Agreement [Member]

Increase decrease in intangible assets

50,000

TPR Investments Pty Ltd [Member] | Stock Purchase Agreement [Member]

Amortization expense

$ 170,000

28,333

Estimated useful lives of intangible property

5 years

Number of shares contibuted | shares

3,571,428

TPR Investments Pty Ltd [Member] | Stock Purchase Agreement [Member] | AUD [Member]

Amount payable under the purchase agreement | AUD

AUD 3,500,000

Total payments of acquire assets | AUD

AUD 4,000,000

NomadChoice's [Member] | Maximum [Member]

Indefinite lived intangible assets

215,000

NomadChoice's [Member] | Minimum [Member]

Indefinite lived intangible assets

100,000

NomadChoice's [Member] | Minimum [Member] | Blogger Database [Member]

Indefinite lived intangible assets

$ 115,000

Focus Factor Business [Member]

Aggregate purchase price of business

$ 6,000,000

Amount payable under the purchase agreement

$ 750,000

4,500,000

Focus Factor Business [Member] | January 20, 2017 [Member]

Amount payable under the purchase agreement

$ 750,000

Focus Factor Brand and Patent [Member]

Indefinite lived intangible assets

$ 450,000

Fair value of intangible assets

$ 1,450,000

Estimated useful lives of amortization

5 years

Amortization expense

$ 408,206

$ 384,720

Acquisition - Purchase Price Al

Acquisition - Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values (Details)	Dec. 31, 2016USD ($)
Distribution Option Agreement One [Member]
Accounts Receivable	$ 2,733,167
Inventory	67,113
Intellectual Property	1,000,000
Non-compete provision	50,000
Non-solicitation provision	50,000
Intangible assets-Customer relationships	1,941,030
Goodwill	2,071,517
Accounts Payable	(971,381)
Accrued Expenses	(941,446)
Total Liabilities	6,000,000
Distribution Option Agreement Two [Member]
Accounts Receivable	2,733,167
Inventory	67,113
Intellectual Property	1,450,000
Non-compete provision	50,000
Non-solicitation provision	50,000
Intangible assets-Customer relationships	1,941,030
Goodwill	1,621,517
Accounts Payable	(971,381)
Accrued Expenses	(941,446)
Total Liabilities	6,000,000
Security Agreement [Member]
Accounts Receivable	58,054
Inventory	204,925
Intellectual Property	100,000
License agreement	606,553
Accounts Payable	(51,795)
Accrued Expenses	(148,520)
Total Liabilities	769,217
Contribution Agreement [Member] | Hand MD Corp [Member]
Intellectual Property	100,000
License agreement	1,670,675
Royalty payable	(258,897)
Others	(11,778)
Total Liabilities	1,500,000
Stock Purchase Agreement One [Member] | Breakthrough Products, Inc [Member]
Cash	2,298,619
Accounts Receivable	(68,976)
Inventory	234,709
Prepaid expenses	57,569
Intellectual Property	100,000
Non-compete provision	50,000
Goodwill	3,253,160
Accounts Payable	(741,822)
Accrued Expenses	(2,202,848)
Total Liabilities	2,980,411
Stock Purchase Agreement One [Member] | TPR Investments Pty Ltd [Member]
Cash	1,584,642
Other receivable	30,684
Inventory	134,212
Prepaid expenses	141,070
Fixed Assets, net	5,698
Intangible assets, Net	3,493
Blogger Database	200,000
Customer Database	500,000
Intellectual Property	100,000
Non-compete provision	50,000
Goodwill	6,174,899
Accounts Payable	(77,064)
Accrued Expenses	(56,224)
Dividends Payable	(1,177,152)
Provision for Income Tax	(518,558)
Total Liabilities	7,095,700
Stock Purchase Agreement Two [Member] | Breakthrough Products, Inc [Member]
Cash	2,298,619
Accounts Receivable	(68,976)
Inventory	234,709
Prepaid expenses	57,569
Intellectual Property	250,000
Non-compete provision
Goodwill	1,983,160
Accounts Payable	(741,822)
Accrued Expenses	(2,202,848)
Total Liabilities	1,810,411
Stock Purchase Agreement Two [Member] | TPR Investments Pty Ltd [Member]
Cash	1,584,642
Other receivable	30,684
Inventory	134,212
Prepaid expenses	141,070
Fixed Assets, net	5,698
Intangible assets, Net	3,493
Blogger Database	85,000
Customer Database	715,000
Intellectual Property
Non-compete provision	50,000
Goodwill	6,174,899
Accounts Payable	(77,064)
Accrued Expenses	(56,224)
Dividends Payable	(1,177,152)
Provision for Income Tax	(518,558)
Total Liabilities	$ 7,095,700

Acquisitions - Purchase Price A

Acquisitions - Purchase Price Allocated to Acquisition of Assets (Details)	Dec. 31, 2016USD ($)
Factor Nutrition Labs, LLC [Member]
Total assets acquired	$ 6,000,000
Factor Nutrition Labs, LLC [Member] | January 22, 2015 [Member]
Cash payment	4,500,000
Factor Nutrition Labs, LLC [Member] | January 20, 2016 [Member]
Cash payment	750,000
Factor Nutrition Labs, LLC [Member] | January 20, 2017 [Member]
Cash payment	750,000
Breakthrough Products, Inc [Member] | Stock Purchase Agreement One [Member]
Stock payment	2,550,000
Stock warrants issued	430,411
Total assets acquired	2,980,411
Breakthrough Products, Inc [Member] | Stock Purchase Agreement Two [Member]
Stock payment	1,380,000
Stock warrants issued	430,411
Total assets acquired	1,810,411
TPR Investments Pty Ltd [Member] | Nomad Choice [Member]
Cash payment	2,848,800
Stock issued at closing	1,750,000
Earn-out payment	2,496,900
Total assets acquired	$ 7,095,700

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Valuation allowance percentage	100.00%
Tax expense	$ 944,358	$ 389,945
Percentage of deferred tax asset	637.00%	5.80%
Operating loss carryforwards expiration year	2,035
Breakthrough Products, Inc [Member]
Valuation allowance percentage	100.00%
Net operating loss carryforwards	$ 32,720,733	$ 25,137,583
Breakthrough Products, Inc [Member] | US Tax Authority [Member]
Valuation allowance percentage	100.00%
Net operating loss carryforwards	$ 32,720,733	$ 33,707,458
Percentage of deferred tax asset	34.00%	34.00%

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. Statutory Rate	34.00%	34.00%
U.S. effective rate in excess of AU/CA rate	(1.00%)	(1.00%)
U.S. valuation allowance	(34.00%)	(34.00%)
Foreign Tax - Australia	638.00%	6.80%
Total provision for income taxes	637.00%	5.80%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets	$ 12,950,124	$ 11,460,536
Valuation allowance for deferred tax assets	(12,950,124)	(11,460,536)
Net deferred tax assets

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Bad debt expense		$ 50,000

Accounts Receivable, Net of All

Accounts Receivable, Net of Allowances for Sales Returns and Doubtful Accounts (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Trade accounts receivable	$ 2,195,391	$ 4,101,148
Less allowances		(121,291)
Total accounts receivable, net	$ 2,195,391	$ 3,979,857

Prepaid Expenses - Summary of P

Prepaid Expenses - Summary of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Advances for inventory	$ 188,980	$ 171,494
Media production	207,555	55,849
Insurance	70,392	54,519
Trade shows	46,700	45,700
Deposits	6,228	41,228
Consultants	15,000	24,000
Rent	15,452	16,216
Promotion - Bloggers	426,220
License agreement	258,333
Software subscriptions	88,782
Miscellaneous	24,960	13,428
Total	$ 1,348,602	$ 422,434

Concentration of Credit Risk (D

Concentration of Credit Risk (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash federally insured limit per bank	$ 250,000
Cash uninsured amount	$ 2,038,985	$ 3,453,290
Three Customers [Member] | Accounts Receivable [Member]
Concentration risk percentage	91.00%	93.00%
Three Customers [Member] | Sales Revenue, Net [Member]
Concentration risk percentage	34.00%	73.00%

Concentration of Credit Risk -

Concentration of Credit Risk - Summary of Major Suppliers (Details)	12 Months Ended
	Dec. 31, 2016
Suppliers One [Member]
Name of the Product	FOCUSfactor
Address of the suppliers	Atrium Innovations - Pittsburgh, PA
City of suppliers	Vit-Best Nutrition, Inc. - Tustin, CA
Suppliers Two [Member]
Name of the Product	Flat Tummy Tea
Address of the suppliers	Caraway Tea Company, LLC - Highland, NY
City of suppliers	-
Suppliers Three [Member]
Name of the Product	Neuragen
Address of the suppliers	C-Care, LLC - Linthicum Heights, MD
City of suppliers	-
Suppliers Four [Member]
Name of the Product	UrgentRx
Address of the suppliers	Capstone Nutrition - Ogden, UT
City of suppliers	-
Suppliers Five [Member]
Name of the Product	Hand MD
Address of the suppliers	HealthSpecialty - Santa Fe Springs, CA

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory in transit	$ 104,500

Inventory - Schedule of Carryin

Inventory - Schedule of Carrying Value of Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 474,420	$ 535,908
Components	431,241	115,340
Inventory in transit	104,500
Raw Materials	92,616	35,406
Total inventory	$ 1,102,777	$ 686,655

Fixed Assets and Intangible A57

Fixed Assets and Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Assets
Depreciation expense	$ 44,480	$ 1,513
Amortization expense	1,126,298	606,489
Impairment of intangible assets	$ 193,750	$ 0

Fixed Assets and Intangible A58

Fixed Assets and Intangible Assets - Summary of Fixed and Intangible Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Assets
Property and equipment	$ 308,084	$ 18,187
Less accumulated depreciation	(50,698)	(6,170)
Fixed assets, net	257,386	12,017
FOCUSfactor intellectual property	1,450,000	1,000,000
Intangible assets subject to amortization	5,373,017	5,521,751
Less accumulated amortization	(1,677,583)	(606,489)
Intangible assets, net	$ 5,145,434	$ 5,915,262

Fixed Assets and Intangible A59

Fixed Assets and Intangible Assets - Summary of Estimated Aggregate Amortization Expense (Details)	Dec. 31, 2016USD ($)
Assets
2,017	$ 1,074,650
2,018	1,074,576
2,019	1,074,311
2,020	471,897
2,021

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 22, 2016	Dec. 14, 2015	Apr. 02, 2014	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Options Outstanding, Granted		1,000,000
Proceeds from promissory note						$ 11,500,000
Promissory note converted into number of shares					7,500,000	400,000
Accrued consulting fees per month					$ 481,215	$ 180,000
Bonus paid					481,215	486,958
Outstanding balance of consulting fees					0	0
Due to related party					3,162,060	100,000
Payroll expense					275,913	$ 128,237
Purchase price per share						$ 0.65
Number of common stock purchase					1,456,492
Hand MD LLC [Member]
Outstanding balance of consulting fees					$ 0	0
Percentage of ownership interest					50.00%
Payroll expense					$ 120,000	$ 40,000
Loan Agreement [Member] | Warrant [Member]
Purchase price per share						$ 1
Knight Therapeutics Inc [Member]
Debt instruments interest rate					10.00%
Number of common stock issued	7,500,000
Number of common stock purchase	$ 2,000,000
Knight Therapeutics Inc [Member] | Minimum [Member]
Purchase price per share	$ 0.34
Knight Therapeutics Inc [Member] | Maximum [Member]
Purchase price per share	$ 0.49
Knight Therapeutics Inc [Member] | Warrant [Member]
Cancellation of shares	8,132,002
Knight Therapeutics Inc [Member] | Stock Option [Member]
Cancellation of shares	1,000,000
Purchase price per share	$ 0.25
Knight Therapeutics Inc [Member] | Loan Agreement [Member]
Amount owed to related party					$ 2,752,639	$ 4,267,268
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | NomadChoice's [Member]
Amount owed to related party					3,680,162	3,571,314
Knight Therapeutics Inc [Member] | Security Agreement [Member]
Amount owed to related party					625,000	925,000
Knight Therapeutics Inc [Member] | Royalty Distribution Agreement [Member]
Amount owed to related party					87,678	71,573
Mr. Jack Ross [Member]
Options Outstanding, Granted			1,000,000
Value of granted options			$ 282,000
Proceeds from promissory note				$ 100,000
Debt instruments interest rate				10.00%
Debt instruments maturity date				Oct. 31, 2015
Accrued consulting fees per month					25,000	$ 15,000
Ms. Harshbarger [Member] | Consulting Agreement [Member]
Due to related party					$ 10,000

Accounts Payable and Accrued 61

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Payroll	$ 275,913	$ 128,237
Legal fees	37,546	38,752
Manufacturers	1,459,460	1,527,333
Promotions	1,244,480	1,213,021
Returns allowance	860,126	1,128,133
Customers	401,594	411,033
Interest	31,079	110,754
Royalties	87,677	71,573
Warehousing	19,080	31,748
Others	141,964	371,518
Total	$ 4,558,919	$ 5,032,102

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Dec. 22, 2016	Nov. 12, 2015	Jun. 26, 2015	Jan. 22, 2015	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015
Amount of loan obligation						$ 7,471,148	$ 9,491,319
Common stock purchase price per share							$ 0.65
Amortization of debt discount		$ 2,067,258				1,620,151	$ 5,499,640
Unamortized debt discount							2,536,419
Recognized amortization of deferred financing costs						215,302	154,525
Interest expense paid						(1,567,867)	(958,740)
Number of common stock purchase						1,456,492
Note issued as part of asset purchase agreement							1,500,000
Knight Therapeutics Inc [Member]
Debt instrument interest rate percentage						10.00%
Interest expense paid						$ 59,358	$ 37,372
Number of common stock issued	7,500,000
Number of common stock purchase	$ 2,000,000
Total payments of acquire assets						$ 1,200,000
Knight Therapeutics Inc [Member] | U.S [Member]
Percentage of sale revenue net					2.00%
Knight Therapeutics Inc [Member] | Minimum [Member]
Common stock purchase price per share	$ 0.34
Knight Therapeutics Inc [Member] | Maximum [Member]
Common stock purchase price per share	$ 0.49
Knight Therapeutics Inc [Member] | Maximum [Member] | U.S [Member]
Percentage of sale revenue net					5.00%
Warrant [Member] | Knight Therapeutics Inc [Member]
Cancellation of shares	8,132,002
Stock Option [Member] | Knight Therapeutics Inc [Member]
Common stock purchase price per share	$ 0.25
Cancellation of shares	1,000,000
Warrant and Option [Member]
Number of common stock issued						7,500,000
Number of common stock purchase						$ 1,456,492
June 26, 2015 Security Agreement [Member] | U.S [Member]
Percentage of sale revenue net			5.00%
June 26, 2015 Security Agreement [Member] | Quarter Ending September 30, 2015 [Member]
Note payable			$ 250,000
June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member]
Note payable			700,000
June 26, 2015 Security Agreement [Member] | Minimum [Member] | June 30, 2016 [Member]
Note payable			$ 12,500
Loan Agreement [Member] | ST Warrant [Member]
Common stock purchase price per share							$ 1
Loan Agreement [Member] | Warrant [Member]
Common stock purchase price per share							$ 1
Subscription Agreement [Member] | Knight Therapeutics Inc [Member]
Number of common stock issued	7,500,000
Number of common stock purchase	$ 2,000,000
Subscription Agreement [Member] | Knight Therapeutics Inc [Member] | Minimum [Member]
Common stock purchase price per share	$ 0.34
Subscription Agreement [Member] | Knight Therapeutics Inc [Member] | Maximum [Member]
Common stock purchase price per share	$ 0.49
Subscription Agreement [Member] | Warrant [Member] | Knight Therapeutics Inc [Member]
Cancellation of shares	8,132,002
Subscription Agreement [Member] | Stock Option [Member] | Knight Therapeutics Inc [Member]
Common stock purchase price per share	$ 0.25
Cancellation of shares	1,000,000
Subscription Agreement [Member] | November 12, 2015 Loan [Member] | Knight Therapeutics Inc [Member]
Number of common stock issued	7,500,000
Number of common stock purchase	$ 2,000,000
Subscription Agreement [Member] | November 12, 2015 Loan [Member] | Knight Therapeutics Inc [Member] | Minimum [Member]
Common stock purchase price per share	$ 0.34
Subscription Agreement [Member] | November 12, 2015 Loan [Member] | Knight Therapeutics Inc [Member] | Maximum [Member]
Common stock purchase price per share	$ 0.49
Subscription Agreement [Member] | November 12, 2015 Loan [Member] | Warrant [Member] | Knight Therapeutics Inc [Member]
Cancellation of shares	8,132,002
Subscription Agreement [Member] | November 12, 2015 Loan [Member] | Stock Option [Member] | Knight Therapeutics Inc [Member]
Common stock purchase price per share	$ 0.25
Cancellation of shares	1,000,000
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member]
Debt instrument interest rate percentage				0.00%
Note issued as part of asset purchase agreement				$ 1,500,000
Note maturity date				Jan. 20, 2017
Note payable						750,000	$ 1,500,000
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2016 [Member]
Note payable				$ 750,000
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2017 [Member]
Note payable				750,000
Security Agreement [Member] | June 26, 2015 Security Agreement [Member]
Unamortized debt discount						2,600
Deferred financing costs						10,486
Recognized amortization of deferred financing costs						5,243	2,643
Interest expense paid						59,358	37,372
Present value of future payments						290,947	531,589
Knight Therapeutics Inc [Member] | Warrant and Option [Member]
Extinguishment of debt						912,267
Knight Therapeutics Inc [Member] | Loan Agreement [Member]
Loan amount		5,500,000		6,000,000
Expences associated with loan		$ 24,000		$ 40,000
Debt instrument interest rate percentage		15.00%		15.00%
Convertible equity offering				$ 1,000,000
Change in loan interest rate		13.00%		13.00%
Revenue				$ 13,000,000
Net income (loss)				$ 2,000,000
Amount of loan obligation						2,812,500	4,875,000
Common stock purchase price per share		$ 0.49
Percentage of shares purchaseable under warrants		6.50%
Unamortized debt discount						1,012,419	1,928,686
Deferred financing costs						289,045
Recognized amortization of deferred financing costs						92,976	136,207
Interest expense paid						625,359	805,686
Accrued interest expense						0	0
Note maturity date		Nov. 11, 2017
Warrants term		10 years
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | ST Warrant [Member]
Number of warrants to purchase common stock				4,595,187
Warrants exercise price				$ 1
Beneficial conversion feature of warrants				$ 1,952,953
Amortization of debt discount							1,952,953
Unamortized debt discount							607,732
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | LT Warrant [Member]
Number of warrants to purchase common stock				3,584,759
Warrants exercise price				$ 0.34
Common stock purchase price per share				$ 1
Percentage of shares purchaseable under warrants				25.00%
Beneficial conversion feature of warrants				$ 1,462,560
Amortization of debt discount						607,732	854,828
Unamortized debt discount							$ 607,732
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares [Member]
Number of warrants to purchase common stock		5,550,625
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares [Member] | Maximum [Member]
Number of warrants to purchase common stock		4,547,243
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | January 22, 2015 Loan One [Member]
Debt instrument interest rate percentage				5.00%
Amount of loan obligation				$ 300,000
Aggregate consideration to be paid				100,000
Capital expenditures				100,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants One [Member]
Number of warrants to purchase common stock		4,547,243					4,547,243
Amortization of debt discount		$ 2,067,258				1,012,419	$ 138,571
Unamortized debt discount						$ 59,861
Number of warrants outstanding						4,547,243	4,547,243
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants [Member]
Number of warrants to purchase common stock		5,550,625					5,550,625
Amortization of debt discount		$ 2,553,287					$ 2,553,287
Unamortized debt discount						$ 101,088
Deferred financing costs						233,847
Recognized amortization of deferred financing costs						117,083	15,675
Interest expense paid						767,904	110,753
Accrued interest expense						31,079	110,753
Note payable						3,781,250	$ 5,500,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Origination Fee [Member]
Expences associated with loan		110,000		120,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Work Fee [Member]
Expences associated with loan		$ 55,000		$ 60,000
Knight Therapeutics Inc [Member] | Subscription Agreement [Member]
Extinguishment of debt						$ 916,267
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member]
Debt instrument interest rate percentage			0.00%
Note issued as part of asset purchase agreement			$ 950,000
Total payments of acquire assets			$ 1,200,000
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member] | U.S [Member]
Percentage of sale revenue net			2.00%

Notes Payable - Schedule of Loa

Notes Payable - Schedule of Loan Payable (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Loans payable	$ 7,634,697	$ 12,406,589
Unamortized debt discount		(2,536,419)
Unamortized debt issuance cost	(163,549)	(378,852)
Total	7,471,148	9,491,319
Less: Current portion	(6,640,903)	(3,775,669)
Long-term portion	$ 830,245	$ 5,715,650

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Apr. 17, 2014	Dec. 31, 2016	Dec. 31, 2015	Jul. 30, 2014
Common stock, shares authorized		300,000,000	300,000,000
Common stock par value		$ 0.00001	$ 0.00001
Forward stock split	30 for 1 forward stock split
Common stock, shares issued		88,764,357	81,692,954
Common stock purchase price per share			$ 0.65
Common stock value		$ 888	$ 817
Common stock issued for cash shares			40,000
Number of shares issued for services		$ 50,000	$ 28,000
Number of shares cancelled		7,500,000
Cancellation of common stock		$ (125,000)
Number of shares commited to issue		125,000
Settlement expense		$ 56,250
Number of common stock issued		$ 1,456,492
Common stock, shares outstanding		88,764,357	81,692,954
Common Stock [Member]
Common stock, shares issued		213,742
Common stock purchase price per share		$ 0.32
Number of shares issued for services			$ 68,000
Common Stock One [Member]
Common stock, shares issued		71,248
Common stock purchase price per share		$ 0.70
Accounts Payable [Member]
Common stock purchase price per share			$ 0.70
Common stock issued for cash shares			292,857
Note Holder [Member]
Common stock, shares issued			400,000
Common stock purchase price per share			$ 0.25
Common stock value			$ 100,000
Former Shareholder [Member]
Number of shares cancelled		713,767
Cancellation of common stock		$ 125,000
Contribution Agreement [Member] | Hand Md Corp [Member]
Common stock, shares issued			2,142,857
Common stock purchase price per share			$ 0.70
Percentage of outstanding capital			50.00%
Stock Purchase Agreement [Member] | NomadChoice Pty Limited's [Member]
Common stock, shares issued			3,571,428
Common stock purchase price per share			$ 0.35
Percentage of outstanding capital			100.00%
Stock Purchase Agreement [Member] | Breakthrough Products, Inc [Member]
Common stock, shares issued			3,000,000
Common stock purchase price per share			$ 0.85
Percentage of outstanding capital			100.00%
ST Warrant [Member] | Loan Agreement [Member]
Common stock, shares issued			4,595,187
Common stock purchase price per share			$ 1
Warrant [Member] | Loan Agreement [Member]
Common stock, shares issued			5,550,625
Common stock purchase price per share			$ 1
Warrant and Option [Member]
Number of common stock issued shares		7,500,000
Number of common stock issued		$ 1,456,492
Board of Directors [Member] | Minimum [Member]
Common stock, shares authorized				75,000,000
Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized				300,000,000

Commitments and Contingencies65

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 08, 2014	Apr. 30, 2014	Dec. 31, 2016	Dec. 31, 2015
Operating lease expiration date		Mar. 31, 2017
Rent expense			$ 5,500	$ 4,480
Subsidiary [Member]
Rent expense	$ 894
Lease term	36 months
AUD [Member]
Rent expense				$ 5,900
March 2017 [Member]
Rent expense			8,923
Sublease rent			$ 3,010

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments For Operating Leases (Details)	Dec. 31, 2016USD ($)
2,017	$ 35,659
Total	35,659
Subsidiary [Member]
2,017	9,834
Total	$ 9,834

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	Jul. 04, 2016	Apr. 18, 2016	Feb. 18, 2016	Dec. 14, 2015	Apr. 02, 2014	Dec. 31, 2016	Dec. 31, 2015	Jul. 30, 2014
Options outstanding, granted				1,000,000
Stock options exercise price per share				$ 0.25
Stock options cancelled during the period						7,500,000
Stock-based compensation expense						$ 2,200,160	$ 523,714
Estimated fair value of company's common stock						$ 0.74
Risk-free interest rate							2.23%
Volatility rate							154.00%
Expected lives							10 years
Dividend yield						0.00%	0.00%
Stock options outstanding intrinsic value						$ 780,000
Minimum [Member]
Estimated fair value of company's common stock						$ 0.40
Risk-free interest rate						0.90%
Volatility rate						135.00%
Expected lives						3 years
Maximum [Member]
Estimated fair value of company's common stock						$ 0.61
Risk-free interest rate						1.24%
Volatility rate						160.00%
Expected lives						6 years
Mr. Jack Ross [Member]
Options outstanding, granted					1,000,000
Stock options exercise price per share					$ 0.25
Two Board Members [Member]
Options outstanding, granted				1,000,000
Stock options exercise price per share				$ 0.25
Two Employees [Member]
Options outstanding, granted				1,000,000
Stock options exercise price per share				$ 0.65
Employee [Member]
Options outstanding, granted	500,000	500,000	300,000
Stock options exercise price per share	$ 0.70	$ 0.70	$ 0.70
2014 Equity Incentive Plan [Member]
Common stock shares reserved for issuance								15,525,000

Stock Options - Summary of Opti

Stock Options - Summary of Options Outstanding by Price Range (Details) - Stock Option Plan [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Options Outstanding, exercise price Lower limit	$ 0.25
Options Outstanding, exercise price Upper limit	$ 0.70
Options Outstanding, Number Outstanding | shares	6,300,000
Options Outstanding, Remaining Average Contractual Life	6 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ .47
Options Exercisable, Number Exercisable | shares	3,408,333
Options Exercisable, Weighted Average Exercise Price	$ .38

Stock Options - Summary of Stoc

Stock Options - Summary of Stock Options Activity (Details) - $ / shares	Dec. 14, 2015	Dec. 31, 2016	Dec. 31, 2015
Options Outstanding, Granted	1,000,000
Weighted Average Exercise Price, Exercised	$ 0.25
Stock Option Plan [Member]
Options Outstanding, Outstanding at Beginning balance		5,000,000	1,000,000
Options Outstanding, Granted		2,300,000	4,000,000
Options Outstanding, Exercised
Options Outstanding, Expired or canceled		(1,000,000)
Options Outstanding, Outstanding at Ending balance		6,300,000	5,000,000
Weighted Average Exercise Price, Outstanding at Beginning balance		$ 0.41	$ .25
Weighted Average Exercise Price, Granted		.50	.45
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired or canceled		(0.25)
Weighted Average Exercise Price, Outstanding at Ending balance		$ 0.47	$ 0.41

Stock Warrants - Summary of War

Stock Warrants - Summary of Warrants Outstanding by Price Range (Details) - Warrant [Member] - Exercise Price Range One [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Warrants Outstanding, exercise prices	$ 5
Warrants Outstanding, Number Outstanding | shares	1,000,000
Warrants Outstanding, Remaining Average Contractual Life	1 year 11 months 16 days
Warrants Outstanding, Weighted Average Exercise Price	$ 5
Warrants Exercisable, Number Exercisable | shares	1,000,000
Warrants Exercisable, Weighted Average Exercise Price	$ 5

Stock Warrants - Summary of Sto

Stock Warrants - Summary of Stock Warrants Activity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options Outstanding, Beginning balance	9,132,002
Options Outstanding, Granted		19,277,814
Options Outstanding, Exercised		(10,415,812)
Options Outstanding, Expired or canceled	(8,132,002)
Options Outstanding, Ending balance	1,000,000	9,132,002
Options Outstanding, Weighted Average Exercise Price, Beginning balance	$ 0.92
Weighted Average Exercise Price, Granted		0.44
Weighted Average Exercise Price, Exercised		0.0000
Weighted Average Exercise Price, Expired or canceled	(0.42)
Options Outstanding, Weighted Average Exercise Price, Ending balance	$ 5	$ 0.92

Derivatives (Details Narrative)

Derivatives (Details Narrative) - USD ($)	Dec. 23, 2016	Nov. 12, 2015	Dec. 31, 2016	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value of derivative liability		$ 2,067,258		$ 3,096,179
Fair values of embedded derivative		2,067,258
Amortization of debt discount		$ (2,067,258)	$ (1,620,151)	(5,499,640)
Loss (gain) on change in fair value of derivative liability			$ 1,380,600	$ 1,028,921
Issuance of common stock to derivative liability			7,500,000	400,000
Warrants cancelled amount	$ 1,715,579

Derivatives - Schedule of Assum

Derivatives - Schedule of Assumptions Used For Fair Value of Derivative (Details) - Derivative [Member]	Dec. 23, 2016	Nov. 12, 2015	Dec. 31, 2015
Risk-free interest rate	2.55%	2.32%	2.27%
Expected remaining term	8 years 11 months 1 day	10 years	9 years 9 months
Expected volatility	143.15%	157.56%	152.07%
Dividend yield	0.00%	0.00%	0.00%

Derivatives - Summarizes Deriva

Derivatives - Summarizes Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Gain on change in fair value of the derivative liabilities	$ (1,380,600)	$ 1,028,921
Level 3 [Member]
Balance	3,096,179
Extinguishment of derivatives liabilities from cancellation of warrants	(1,715,579)
Gain on change in fair value of the derivative liabilities	(1,380,600)
Balance		$ 3,096,179

Segments (Details Narrative)

Segments (Details Narrative)	12 Months Ended
	Dec. 31, 2016Segment
Segment Reporting [Abstract]
Number of operating segments	1

Segments - Summary of Net Sales

Segments - Summary of Net Sales Attributed to Customers Geographical Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 34,840,394	$ 13,456,377
United States [Member]
Revenue	32,010,018	13,129,753
Foreign Countries [Member]
Revenue	$ 2,830,376	$ 326,624

Segments - Summary of Net Sal77

Segments - Summary of Net Sales Attributed to Customers Product Group (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 34,840,394	$ 13,456,377
Nutraceuticals [Member]
Revenue	33,877,529	13,030,006
Over the Counter (OTC) [Member]
Revenue	907,401	416,417
Cosmeceuticals [Member]
Revenue	$ 55,464	$ 9,954

Segments - Summary of Net Sal78

Segments - Summary of Net Sales Attributed to Customers Product Group (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Other [Member] | Sales Revenue, Net [Member]
Concentration risk percentage	10.00%	10.00%

Segments - Summary of Long-live

Segments - Summary of Long-lived Assets (Net) Attributable to Operations Geographical Segment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Long-lived assets net	$ 13,196,060	$ 17,423,679
United States [Member]
Long-lived assets net	13,174,461	17,411,598
Foreign Countries [Member]
Long-lived assets net	$ 21,599	$ 12,081

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - During 2017 [Member]	12 Months Ended
	Dec. 31, 2016USD ($)
Factor Nutrition Labs [Member]
Repayment of loan	$ 750,000
Outstanding balance	0
Knight Therapeutics [Member] | Second Loan [Member]
Repayment of loan	$ 1,031,250